Podcasts about Performance measurement

Your competitors are already using AI. Don't get left behind. Weekly strategies used by PE Backed and Publicly Traded Companies →https://hi.switchy.io/U6H7S--In this episode, Ryan Staley and Brandon Taylor discuss the critical role of company culture in the context of AI-led transformations. They explore how to assess leadership and team dynamics, set expectations for change, and ensure cross-functional alignment. Brandon emphasizes the importance of a world-class culture, the need for personal alignment with company goals, and the use of scorecards to measure performance effectively.Chapters00:00 The Importance of Company Culture in AI Transformation02:51 Assessing Leadership and Team Dynamics05:56 Setting Expectations for Change and Growth09:04 Cross-Functional Alignment for Success11:50 Utilizing Scorecards for Performance Measurement

Chapters 00:00 Introduction to Finger Tendons and Climbing Injuries 03:13 Understanding Finger Anatomy and Function 06:02 Common Finger Injuries in Climbers 08:53 Pathophysiology of Tenosynovitis 12:06 Rehabilitation Strategies for Finger Injuries 15:04 Comparing Tenosynovitis and Pulley Injuries 17:56 Managing Climbing Volume and Injury Prevention 25:38 Understanding Power Loss in Climbing 29:27 Tendon Adaptation Through Lifelong Loading 33:22 Rehabilitation Challenges for Climbers 35:05 The Role of Strength Training in Climbing 37:10 Tendon Adaptation Mechanisms 38:56 Controversies in Climbing Training Methods 41:07 Ultrasound in Diagnosing Climbing Injuries 42:22 Using Strain Gauges for Performance Measurement 43:53 Understanding Pulley Ruptures 45:36 Rehabilitation Techniques for Finger Tendons 47:14 Thumb Tendon Issues in Climbers 49:09 Future Directions in Climbing Research 50:07 Finding Professional Help in Climbing Rehabilitation   Takeaways Tyler Nelson has a doctorate in chiropractic and a master's in tendon research. Rock climbers often experience finger injuries due to overtraining. Finger tendons are unique in their anatomy and function compared to other tendons. Tenosynovitis is a common injury among climbers, often due to too much stress too soon. Rehabilitation for finger injuries should focus on gradual load increase and proper technique. The A2 pulley is crucial for finger movement and is often injured in climbers. Climbers need to be aware of the specific loads their fingers endure during training. Managing climbing volume is essential to prevent injuries in climbers. The tendon sheath plays a vital role in the health of finger tendons. Understanding the mechanics of finger tendons can aid in better training and injury prevention. Power loss is a key metric in understanding climbing performance. Beginners should focus on skill development rather than overloading their fingers. Body weight significantly affects the load on tendons during climbing. Lifelong loading is crucial for tendon adaptations in climbers. Climbers often underload their tendons during rehabilitation, leading to prolonged recovery. Strength training is essential for injury prevention and performance enhancement in climbing. Tendon adaptations require significant muscle load and proper joint positioning. Controversial training methods are gaining popularity, but their efficacy is debated. Ultrasound is the gold standard for diagnosing climbing injuries and assessing tendon health. There is a growing interest in climbing research, leading to better understanding and treatment of climbing-related injuries. Instagram: https://www.instagram.com/c4hp/ Website: https://www.camp4humanperformance.com Notes: https://jackedathlete.com/podcast-142-finger-tendons-with-tyler-nelson/

Today on the podcast we hear from Dan Lust, Beverage Industry Consultant with Pints, LLC.Dan and I review the top challenges facing the industry and share data analytics, business planning, and performance measurement tactics for distributors and breweries. SummaryHot topics: Tariffs, pricing, and the importance of sales trainingStrategic growth planning tactics for breweries Tools to make data-driven decisionsKeys to brewery-wholesaler business relationshipsResourcesConnect with Dan at Pints, LLCGet the FREE beer wholesaler financial newsletter

Send us a textIn this episode of Definitely Maybe Agile, hosts Peter Maddison and David Sharrock dive into the world of Objectives and Key Results (OKRs). They explore how this increasingly popular framework helps organizations create alignment, measure progress, and foster autonomy while moving away from traditional KPIs. From the origins at Intel in the 70s to widespread adoption by tech giants like Google, Peter and David discuss the nuances of implementing OKRs effectively and why they're particularly well-suited for organizations operating in rapidly changing environments.This week´s takeaways:Unlike KPIs which measure performance, OKRs measure progress and alignment to strategy. They should never be tied to individual performance metrics as this undermines their exploratory nature.Successful OKR implementation requires ongoing conversations, regular reviews, and a cultural shift. Many organizations underestimate the effort needed to maintain OKRs effectively.Effective OKRs should be limited in number (3-5 objectives with 3-5 key results each), represent stretch goals beyond business-as-usual, and serve as a prioritization mechanism for the organization.

The majority of active managers underperform their benchmarks - but why?   In this episode of the Global Thinking Podcast Rob sits down with Dr. Joseph Nelesen, Head of Specialists, Index Investment Strategy at S&P Dow Jones Indices, to unpack the 2024 SPIVA Report—the definitive study comparing active fund managers to their benchmarks.   The discussion explores how most active managers have underperformed their benchmark, the critical role of survivorship bias, and the impact of fees and market conditions on long-term performance. Joe shares eye-opening statistics including how almost half of all funds over a 10 year period cease to exist and the fact that zero managers maintain their top quartile ranking over a five-year period.   Rob and Joe also dive into ETF investing, analyzing the trends shaping active management today and what investors should consider when building portfolios. Whether you're an investment professional or an individual investor, this conversation delivers valuable insights into the ongoing debate between active versus index strategies and how market efficiency may be impacting your investment decisions.   https://www.indexologyblog.com/2025/01/08/shifting-tides-concentration-dispersion-and-the-sp-500-risk-landscape/     Chapters   00:00 Introduction to Global Thinking Podcast 01:07 Meet Dr. Joseph Nelesen 05:53 Understanding the SPIVA Report 13:15 Key Findings from the 2024 Report Card 19:04 The Challenge of Persistence in Active Management 25:54 Trends in Active Management and ETF Usage 27:57 Exploring Fixed Income Strategies 30:41 The Dynamics of Equal Weighting in S&P 500 31:55 Active vs. Passive Investing: A Deep Dive 35:06 The Role of Fees in Investment Performance 38:27 Understanding Long-Term Underperformance Trends 39:36 Due Diligence in Selecting Active Managers 41:52 The Evolution of Market Efficiency 44:22 Personal Insights and Recommendations   Disclosures: https://forstrong.com/disclosures/  Global Thinking Podcast Series - https://forstrong.com/podcast/  Global Thinking Insights - https://forstrong.com/insights/  Who is Forstrong Global - https://forstrong.com/who-we-are/  Ask Forstrong - https://forstrong.com/category/ask-forstrong/  Invest With Us - https://forstrong.com/invest-with-us/         

How can balanced scorecards and KPIs transform your business success? Well-designed performance metrics bring transparency, align teams, and streamline decision-making processes. In this episode of The Agency Blueprint, we discuss the transformative potential of balanced scorecards and well-structured key performance indicators (KPIs) for businesses. We also explain how to break down long-term objectives into actionable department-specific goals. Listen in to learn how full transparency with your team helps build trust and drive the business vision forward. You will also learn the importance of clarity, timeliness, and focus in KPI tracking to avoid vanity metrics. Key Questions: [01:40] What level of data transparency do you maintain with your team? [06:44] Are your KPIs aligned with your business's true pain points and opportunities for growth? [11:04] How can you effectively translate your 3-5-year objectives into clear annual and departmental goals? [21:21] Are you tracking meaningful KPIs or focusing on vanity metrics that don't contribute to real growth? What You'll Discover: [02:09] How full transparency with your team helps build trust and drive the business vision forward. [03:56] How to distinguish between valuable and motivated team members and those who may harm team morale. [06:20] The importance of identifying core inputs and aligning them with your business goals to avoid chasing irrelevant metrics. [11:15] How to break down long-term business objectives into specific, actionable goals for each year. [14:25] How to establish clear departmental and individual metrics to ensure accountability and progress tracking. [16:09] The motivational impact of using leaderboards to foster healthy competition and engagement within teams. [17:47] Common pitfalls in KPI tracking and why focusing on meaningful data is crucial for business growth and effective decision-making.

This week, we are joined by KPI Guru Bernie Smith - world-renowned expert and author of 21 books...Bernie has made a career out of successfully helping people from across the globe to identify how they use KPIs to unlock performance. In this first episode, Bernie shares how to identify the KPIs that will give you the edge with practical insights and engaging stories. It is hard to believe that KPIs can be so interesting.And, of course, we'll get another dose of middle class smugness from James as his Volvo and its heated seats give him the edge this winter!Next week, Bernie will be back to help us unlock 'gold bar' KPIs

In a recent episode of A Modern Nonprofit Podcast, host Tosha Anderson sat down with Greg Miller, President and CEO of Penn-Mar Human Services, to discuss the critical issues of recruitment, retention, and strategic partnerships in the nonprofit sector. With over three decades of experience in human services and nonprofit management, Miller shared valuable insights on how organizations can attract and retain top talent while fostering meaningful partnerships. Mission-Driven Recruitment Miller emphasized the significance of hiring for mission rather than just function. He stressed that potential employees and volunteers should have a clear understanding of how their work contributes to the organization's overall mission. This approach not only attracts individuals who are passionate about the cause but also helps in retaining them for the long term. At Penn-Mar, the focus is on helping recruits understand how they fit into the organization's mission of supporting people with disabilities. This clarity of purpose has been instrumental in attracting high-caliber talent and reducing turnover rates. About Greg Miller To learn more about Penn-Mar Human Services and Greg Miller's work, visit https://www.penn-mar.org/. You can find him on LinkedIn here:   / gregory-miller-12154031   Gregory T. Miller is the President and Chief Executive Officer of Penn-Mar Human Services and also serves as the CEO of the Penn-Mar Foundation. As the organizational leader since 2012, he has direct responsibility for the programmatic, financial, and strategic operations of Penn-Mar, including Board development. Since joining the organization in 1988, he has served in various leadership roles, most recently as President and Chief Operating Officer. Greg holds a bachelor's degree from Shippensburg University and a master's degree from McDaniel College. He earned a Certificate for Performance Measurement for Management of NPOs from Harvard University Kennedy School of Government and a Certificate for Strategic Perspectives in Non-Profit Management from Harvard Business School. On three separate occasions, Greg has addressed the International Conference in Sao Paulo, Brazil on leadership development and employment and service models for people with disabilities. What to watch next… Here is Alex Johnston talking about strategic relationships with high net worth individuals:    • Episode 99: Unlocking the Potential o...   Nonprofit Priorities and Time Management with Alisa Johnson:    • Episode 79: Nonprofit priorities and ...   What's new on our website? The Ultimate Guide to KPIs in Your Nonprofit: https://thecharitycfo.com/kpis-you-sh... Follow Us Online Stay connected and get more exclusive content on: Website: www.thecharitycfo.com Instagram: @thecharitycfo Facebook:   / thecharitycfo   LinkedIn: https://www.linkedin.com/company/the-... TikTok: @thecharitycfo Spotify: https://open.spotify.com/show/6hofQXP... Apple Music: https://podcasts.apple.com/us/podcast... Get Involved Subscribe for more videos: Don't forget to hit the bell icon so you never miss a video! Explore A Modern Nonprofit Podcast:    • A Modern Nonprofit   About The Charity CFO We are an accounting partner that truly understands nonprofits. We know the missions that drive you, the obstacles that challenge you, and the dedication your job demands. We “get” nonprofits, because nonprofits are all that we do. If you need help with your accounting and bookkeeping, let's talk. Book a FREE consultation here.

⁠⁠⁠

Special guest David Kanter of ML Commons joins Shahin Khan and Doug Black to discuss AI performance metrics. In addition to the well-known MLPerf benchmark for AI training, ML Commons provides a growing suite of benchmarks and data sets for AI inference, AI storage, and AI safety. David is a founder, board member of ML Commons and the head of MLPerf benchmarks. [audio mp3="https://orionx.net/wp-content/uploads/2024/11/091@HPCpodcast_SP_David-Kanter_AI-Performance_ML-Commons_20241107.mp3"][/audio] The post @HPCpodcast-91: David Kanter of ML Commons on AI Performance Measurement appeared first on OrionX.net.

Is “multitasking” truly efficient? Does it leave you feeling unfocused and anxious? In this episode, we're talking with Namita Tated about how “multitasking” is often just rapidly changing tasks and more time consuming than time saving.   Namita Tated is a Portfolio Associate at Build Asset Management in East Seattle, where she oversees Fund Accounting, Financial Reporting, and Performance Measurement. With a background in Finance and Accounting, Namita has previously worked with KPMG and BNY Mellon, gaining extensive experience in the financial industry.  Kristine Delano guides the conversation on how taking a more mindful approach to completing tasks may enhance productivity and well-being. Follow on Instagram kristine.delano.writer  Visit www.womeninetfs.com to find additional support in the ETF industry.  Go to www.kristinedelano.com for your Thrive Guide: a compilation of the most requested and insightful advice from our guests on Leadership and Advancement.

Send us a textJoin me for a deep dive into the world of family offices and investment strategies! In this video, I'll share insights from my 17 years of experience running the Investor Club, where we've hosted over 2,000 speakers and fostered countless connections.Throughout the day, I'll be moderating panels and delivering two impactful 15-minute talks designed to maximize your return on investment. Whether you're an investor, CEO, or looking to raise capital, my goal is to equip you with $100,000 worth of actionable insights.I'll also be discussing key takeaways from my recent interview with Dr. Robert Cialdini, a leading expert on influence. He revealed powerful strategies to enhance your effectiveness in securing investments and partnerships.Plus, I'll share personal stories and experiences from my travels, including adventures in Machu Picchu and the Grand Canyon, along with insights into the family office landscape.You won't want to miss our discussions on the importance of ethical influence, deal structures, and the mindset of successful founders. Learn how to build genuine relationships that can transform your business trajectory.Stay tuned as we explore how to navigate this dynamic industry and make meaningful connections that could change your life!Don't forget to like, subscribe, and hit the notification bell to stay updated on all our future content!#FamilyOffice #InvestmentStrategies #EntrepreneurshipHere is the Youtube Video https://youtu.be/_RagjUqL168

Send us a textIn this week's podcast episode, we are joined by one of our Advisory Board members, Dr. Joan Johnston, to talk about why high functioning teams fail. With over 30 years of experience working with the Department of Defense, Dr. Johnston is an expert on decision making and simulation training. Throughout her career she has made a significant impact on advancing the science of Learning, Team Training, Decision Making under Stress, Performance Measurement, and Organizational Development.For this episode, we use the tragic incident involving the USS Vincennes where the guided missile destroyer accidentally shot down an Iranian passenger plane after mistaking it for an F-14 fighter jet, as a focal point of the discussion. Dr. Johnston walked us through the critical errors that were made during that incident, the role that stress plays on communication and decision-making, and she shares her insights on what it takes to build more resilient, high-performing teams.This episode is a powerful reminder of the human factors that influence decision-making and how easily things can go wrong—even with the best of teams. But it also provides a hopeful message: with effective training, strong leadership, and a commitment to learning from past mistakes, we can build teams that are more resilient, adaptable, and prepared to handle the challenges they face.Thank you so much for tuning in, we hope you enjoy the episode and please check out our Patreon channel where we have a lot more content, as well as subscriber only episodes of the show. If you enjoy the podcast, I will kindly ask that you leave us a review and more importantly, please share it with a friend. Thank you for your time and don't forget that Training Changes Behavior!Episode Linkshttps://www.ahrq.gov/teamstepps-program/index.htmlhttps://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2019.01480/fullSupport the showWebsite: https://thehumanbehaviorpodcast.buzzsprout.com/shareFacebook: https://www.facebook.com/TheHumanBehaviorPodcastInstagram: https://www.instagram.com/thehumanbehaviorpodcast/ Patreon: https://www.patreon.com/ArcadiaCognerati More about Greg and Brian: https://arcadiacognerati.com/arcadia-cognerati-leadership-team/

Highlights from this week's conversation include:Matt's Background and Experience in VC (0:10)Challenges in Venture Capital Allocations (2:20)Understanding the Allocator's Perspective (4:32)Technology's Impact on Allocators (7:02)Direct Investments vs. Outsourced CIOs (10:04)Using Third-Party Reports for Performance Measurement (14:14)Understanding Performance Metrics (16:12)Venture Capital Landscape (17:50)Insider Segment: The Importance of Diversifying Funding Sources (19:31)Extending Your Runway and Preserving Equity (22:06)Engaging with Camber Road (22:57)Insurance Allocators' Strategy (24:55)MetLife's Venture History (26:40)Innovation Office Impact (27:53)New Pools of Capital (31:29)Balanced Portfolio Insights (34:25)Investment Strategies for New Investors (34:52)The Challenge of Investor Sentiment (37:00)The Importance of Manager Selection (40:09)Contrarian Investment Strategies (41:36)Final Thoughts and Takeaways (44:14)Matt Curtolo is a seasoned investor with 20+ years covering all functional areas of the private markets from both an allocator and investor lens. Most recently, he built the investment capability from the ground up at a fintech start-up called Allocate, focused on offering high-quality venture capital and alternative investment opportunities to a broader investor base. Previously, he was a co-manager of MetLife's Alternative Investments Portfolio and Head of Private Equity at a large independent OCIO. Matt began his career at Hamilton Lane (NASDAQ: HLNE) during its early growth, before it became the world's pre-eminent private markets allocator. Camber Road is the most cost-effective, flexible and nimble leasing company for venture-backed businesses. We are experienced, but not stodgy. We're hungry, like the startup companies we serve. And we hold every lease on our balance sheet. We finance business-essential equipment for venture-backed companies. We do one thing, and we do it better than the rest. Learn more at www.camberroad.com. Swimming with Allocators is a podcast that dives into the intriguing world of Venture Capital from an LP (Limited Partner) perspective. Hosts Alexa Binns and Earnest Sweat are seasoned professionals who have donned various hats in the VC ecosystem. Each episode, we explore where the future opportunities lie in the VC landscape with insights from top LPs on their investment strategies and industry experts shedding light on emerging trends and technologies. The information provided on this podcast does not, and is not intended to, constitute legal advice; instead, all information, content, and materials available on this podcast are for general informational purposes only.

In this episode, Ray Sclafani discusses the seven essential metrics for a CEO scorecard that can help measure the performance of financial advisory firm CEOs. The metrics cover various categories such as firm performance, strategic leadership, operational excellence, stakeholder relations, personal development, adaptability and crisis management, and long-term sustainability. Ray provides detailed explanations for each metric and encourages CEOs to set specific measurable targets for each area. He also emphasizes the importance of regularly reviewing and assessing the CEO's performance using the scorecard.Key TakeawaysA CEO scorecard can help measure the performance of financial advisory firm CEOs.The scorecard should include metrics in categories such as firm performance, strategic leadership, operational excellence, stakeholder relations, personal development, adaptability and crisis management, and long-term sustainability.Setting specific measurable targets for each metric is important.Regularly reviewing and assessing the CEO's performance using the scorecard is crucial for improvement and growth.To check out this article from The ClientWise Blog click here.Find Ray and the ClientWise team on LinkedIn | X | Instagram | Facebook

Mark Friedberg, MD, SVP of Performance Measurement & Improvement at Blue Cross Blue Shield of Massachusetts joins the podcast to discuss key insights into his healthcare career journey, his organization's ‘pay for equity' financial model, advice for healthplan leaders looking to achieve better health equity outcomes for their members, and more.

This Week:  Performance Measurement  There's a systematic method for you to get feedback on your nonprofit's finances; programs, clients; and employees. It's both art and science. Bryan Shane explains this management and decision-making tool. He's co-author of the book, “The … Continue reading →

In this episode of Manufacturing an American Century, host Matt Bogoshian is joined by Phillip Singerman, Ph.D, former U.S. Assistant Secretary of Commerce for Economic Development, Associate Director for Innovation and Industry Services at the National Institute of Standards and Technology, and current AMCC Senior Advisor for Performance Measurement. The two discuss the historical perspective behind today's national industrial policy, and the current rising trend of regionalization and bottom-up leadership that's powering a national manufacturing resurgence.

In this episode of “Inside Health Care,” we take a look back at what we've learned since the pandemic hit over two years ago. We first chat with an upcoming star speaker at NCQA's 2023 Health Innovation Summit on what we've garnered from the growth of telehealth in remote medicine. Then in our second interview in this episode, we discuss the public's conflict with immunization and new strategies on encouraging vaccination.Dr. Leslie Eiland is an Associate Professor of Medicine in the Department of Internal Medicine, Division of Diabetes, Endocrinology & Metabolism at the University of Nebraska Medical Center. She is Medical Director of Patient Experience and Digital Health at Nebraska Medicine, and has been Medical Director of the endocrine telehealth program there since 2014. The program provides care via telehealth to eight rural community hospitals in Nebraska and Iowa. Dr. Eiland's clinical areas of interest and expertise are remote delivery of endocrine care and providing endocrine support for primary care providers in rural communities.For our second interview, we wonder: what have we learned from the pandemic? With backs up against the wall and clinical care pushed to capacity, 2023 was a time of reflection...and re-invigoration. In this interview, hosted by Dr. Sepheen Byron, Assistant Vice President, Performance Measurement at NCQA, you'll hear about one such effort to see what we've learned about, and gain new insights into approaches to care, from review of pandemic care. In this case, we focus on Adult Immunization and improving adult immunization rates.A panel of experts, including partners from NCQA, convened in June of 2023 for a roundtable discussion on adult immunization. They not only discussed clinical guidelines and approaches to better health. They considered simple human behavior: how to rebuild trust with patients and ultimately find new ways to encourage them to vaccinate. In September 2023, NCQA released a white paper summarizing the roundtable's discussions and their conclusions.Megan Lindley, MPH, is the adult vaccination Team Lead of the Applied Research, Implementation Science, and Evaluation Branch in the Immunization Services Division of the CDC. Her areas of research interest include immunization law and policy, adult immunization quality measurement, vaccination in pregnancy and healthcare personnel vaccination. She was an active member from 2012-2019 and a co-chair from 2018-2019 of the National Adult and Influenza Immunization Summit's Quality Measures Workgroup, which developed two immunization quality measures that were added to HEDIS in 2019: a measure of routine adult vaccination and a composite measure of vaccination of pregnant women. Ms. Lindley has authored or co-authored over 100 peer-reviewed publications.In our Fast Facts segment, we observe September's Prostate Cancer Awareness Month with important information from the CDC on symptoms and screening. We also discuss one of a number of NCQA's cancer-related HEDIS screening measures. Colorectal Cancer Screening, which we call C-O-L or C-O-L-E, assesses adults 50–75 who had appropriate screening for colorectal cancer with any of a number of tests, including a colonoscopy every 10 years, computed tomography colonography every 5 years and a stool DNA test every 3 years.

Dr. Joan H. Johnston (Retired) has over 30 years of experience as a Senior Research Scientist with the U.S. Navy and U.S. Army. She has written and collaborated on over 100 publications and has given innumerable presentations and tutorials about her research which has had a significant impact on advancing the science of Learning, Team Training, Decision Making under Stress, Performance Measurement, and Organizational Development. She obtained her M.A. and Ph.D. in Industrial & Organizational Psychology from the University of South Florida. Dr. Johnston's career with the Naval Air Warfare Center Training Systems Division (NAWCTSD) was marked by extensive collaborations across the Department of Defense, academia, and private industry. She was a principal Investigator and project manager for the Office of Naval Research (ONR) sponsored Tactical Decision Making Under Stress (TADMUS) program; ONR recognized her outstanding performance with the Dr. Arthur E. Bisson Prize for Naval Technology Achievement. In 2001 the Society for Industrial and Organizational Psychology also recognized this achievement with the M. Scott Myers Award for Applied Research in the Workplace. In recognition of her sustained performance excellence NAVAIR made Dr. Johnston a Research and Engineering Associate Fellow in 2008. After 22 years Dr. Johnston moved on to a promotionas the U.S. Army Research Institute's Unit Chief in Orlando, and then eventually joined the U.S. Army Research Laboratory as a Senior Scientist at the Simulation Training and TechnologyCenter (STTC). She continued to work across agencies and services in pursuit of advancing the science of team training. She and her colleagues were recognized in 2016 for their outstanding accomplishments with the Department of the Army Achievement Medal for Civilian Service and the NTSA Modeling and Simulation Team Award. Dr. Johnston's leadership on this program Learn more about Joan: Connect on LinkedIn See more of her work Learn more about NDM at NaturalisticDecisionMaking.org. Where to find the hosts: Brian Moon Brian's website Brian's LinkedIn Brian's Twitter Laura Militello Laura's website Laura's LinkedIn Laura's Twitter

In this episode of Dreams With Deadlines, host Jenny Herald interviews strategy execution expert Brett Knowles to explore the intersection of technology, strategy, and execution. Throughout the conversation, Brett shares insights and practical advice on leveraging AI and large language models like ChatGPT to enhance strategy execution.Key Things Discussed: The limitations of traditional approaches and the need for agility in strategy execution. The role of AI in creating an execution ripple and assessing departmental capabilities. Building a lightweight nexus and keeping OKR systems simple for effectiveness. The evolving role of senior leadership and the importance of asking the right questions. Show Notes [00:00:18] Understanding the Distinction: AI and GPT Explained. Jenny and Brett explore the difference between AI and GPT, highlighting GPT's capacity to learn and respond to conditions. [00:02:21] Harnessing GPT's Potential in Strategy Development and Execution: Jenny and Brett discuss the benefits of incorporating GPT into strategy development, testing its recommendations, and achieving a balance between familiar and innovative ideas. [00:06:37] Unlocking the Versatility of GPT in Business Applications: Jenny and Brett explore the various business applications of GPT, including automation, decision-making, recommendation generation, option generation, and strategy evaluation. [00:11:54] Accelerating Strategy Development and Execution with AI: Jenny and Brett highlight how GPT can simplify and enhance the strategy development process, providing examples of idea generation, insights gathering, and automated slide deck creation. [00:17:11] Navigating Limitations and Challenges of GPT in Strategy Development: Jenny and Brett discuss the misconceptions, data input importance, and recognizing GPT's potential to surpass human decision-making quality. [00:23:35] Calibrating Parameters for Enhanced Strategy Execution with GPT: Jenny and Brett explore the significance of parameter calibration in optimizing GPT's performance and overcoming status quo bias. [00:30:40] The Execution Ripple and Building the Nexus for Strategy Execution: Brett delves deeper into the concept of the execution ripple, mapping connections, and enhancing GPT's insights and recommendations. [00:35:12] The Execution Donut and Building a Consistent Model: Jenny and Brett explore the interconnectedness of elements in the execution donut and the importance of a reliable and repeatable decision-making model. [00:38:38] The Evolving Role of Senior Leadership in Strategy Execution: Jenny and Brett discuss the agility needed in strategy execution, asking better questions, and embracing AI-powered strategies for a competitive edge. [00:44:43] Quick-Fire Questions for Brett: What's your Dream With a Deadline: Brett's dream is to share his knowledge with as many people as possible on an ongoing basis. He is passionate about making information available to the community, but there is no specific deadline for this dream. Using Large Language Models (ChatGPT) for OKRs: Brett emphasizes the importance of ownership when considering the use of these technologies for OKRs. If using the tools adds complexity or creates barriers to acceptance, it may not be recommended. However, he believes that organizations will eventually need to move in this direction to succeed with OKRs. Advice for Starting with OKRs: The key advice is to keep it simple. Many OKR systems fail because they become too complex, with too many objectives and key results. It is important to ensure that every individual benefits from using OKRs and that it is not just a reporting system for the leadership team. Excitement about Advancements in Technology for Strategy Execution: Brett is excited about how these advancements allow us to challenge outdated paradigms in strategy development and execution. He believes that traditional approaches, rooted in decades-old knowledge, need to be replaced or reimagined. The new possibilities open up avenues for innovative solutions. Book(s) that Shaped Thinking: Brett recommends anything written by Edward de Bono, who focused on helping the brain become more creative. De Bono's frameworks provide ways to enhance creativity without relying on external substances. Brett also highlights that while there are many business books available nowadays, they often present methodologies as isolated silos. Recognizing the interconnectedness of concepts and joining existing ideas is crucial for creating value. Relevant links: “Can Machines Think?” Alan Turing's decades-old question The Turing Test Kasparov vs. Deep Blue  The Rumsfeld Papers: Known and Unknown The Rumsfeld Matrix Peter Drucker, the Father of Management Thinking Dr. Edward de Bono, the originator of the term Lateral Thinking About the Guest:Brett Knowles is the Founder at Performance Measurement & Management. He is a renowned thought leader with a track record of spearheading strategic execution and driving remarkable performance improvement through rapid OKR implementation. Featured in Harvard Business Review, Forbes, and Fortune for his expertise in the Balanced Scorecard.Follow Our Guest:Website | LinkedIn | YouTubeFollow Dreams With Deadlines:Host | Company Website | Blog | Instagram | Twitter

Patient care comes in all shapes and sizes. It can range from dispensing medications to administering vaccines to leveraging your technology. Whatever your approach to patient care looks like, we all share a common objective: do right by them. Putting the “care” in “patient care,” some of our industry's best and brightest discuss how you can take your pharmacy work — and your — patient's health — to the next level. Tune in to learn how you can make the most out of your pharmacy technology, clinical services, and patient education.  Featured Guests include:  Amina Abubakar, Pharmacy Owner and CEO of the Avant Institute of Clinicians - EP 12 Brandon Knott, Owner of Cascade Specialty Pharmacy - EP 26 T.W. Taylor,  Owner of Williamsburg Drug Company - BTS EP 39   Tana Kaefer, Director of Clinical Services at Bremo Pharmacies - EP 90 Theresa Toll, Pharmacist/Owner of Bay Street Pharmacy - BTS EP 46  Danielle Pierce, Director of Pharmacy Operations at Equitas Health - BTS EP 45  Rob Maher, Director Of Pharmacy Services at Klingensmith's Drug Stores - BTS EP 34 Lisa Hines, VP of Performance Measurement at Pharmacy Quality Alliance (PQA) - EP 20  Barry Klein, Owner of Klein's Pharmacy - BTS EP 20 Looking for more information about independent pharmacy? Visit www.pioneerrx.com

“Do less, but do it fucking phenomenally” Chris Delivered a keynote presentation on Attribution and Measurement at the 2023 SaaStock Conference in Austin. He starts his presentation by discussing the current state of the market, highlighting the fact that companies have less money and marketing budgets are being scrutinized, and the implications of that. He emphasizes the need for companies to scale their projects down to focus on what's working, rather than spreading their resources thin across multiple programs.  Chris then delves into different strategies for capturing and creating demand. He emphasizes the importance of organic thought leadership and content distribution, using platforms like LinkedIn, YouTube Shorts, Reddit, and Quora. He wraps up by covering the need for a new framework for attribution, and then answers audience questions.  Thanks to our friends at Hatch for producing this episode. Get unlimited podcast editing at www.hatch.fm

Welcome to IMpulse, The Influencer Marketing Podcast. I'm your host Prateek Panda, VP of Marketing at Phyllo. Today our guest is Liang Chiu, Director of Influencer Marketing & Brand Partnerships for CTI International BRAND SOCIAL WATCH. Join us as Liang shares his thoughts on how brands should approach influencer marketing, the challenges of matching influencers with brands, and how to measure the results of your campaigns and attain the targeted ROI. Don't miss out on this valuable conversation!

Evaluate and enhance your investment strategies with timely and accurate investment performance measurement and reporting. In this podcast, SS&C Managing Director Julian Webb discusses how technology and services are helping to meet today's performance and reporting expectations, such as: Reduced turnaround time Operational efficiency Customized output and reporting Compelling digital experiences Find out how SS&C can help service your investment performance and reporting.

Episode Description Welcome to another episode of the veterinary business success show. In this brand new episode, we are joined by Chris DeSantis to discuss the generational differences in workplaces. Chris DeSantis is an author, speaker, consultant, and podcast host based in Chicago. He is currently the Pricipal of CPDeSantis.com and podcast host of the Cubicle Confidential Podcast. He has previously worked as the Human Resource Development Manager at Brunswick Corporation, Director of Management Development and Training at The America Medical Association, and as an Associate - Management Development at Arthur Andersen. Over the past fifteen years, he has been invited to speak on generational issues in the workplace at hundreds of the leading U.S. law and accounting firms, as well as many of the major insurance and pharma companies.In this podcast episode, Brendan Howard interviews Chris DeSantis about generational differences in the workplace and how they affect leadership and management. DeSantis discusses the perception of generational differences and how they are more perceptual than actual. He also addresses the issue of "quiet quitting" and disengagement in the workplace, suggesting that employers need to focus on developing and engaging their employees. DeSantis emphasizes the importance of recognizing generational differences in the workplace, but also acknowledges the need to be skeptical of overemphasizing these distinctions. He also suggests creating a database of everything anyone in a company is willing to teach another human being to encourage learning and development.Click here for an extended version of this episode. Enjoy!Episode Outline [00:00] Podcast Intro [02:07] Difference between perceptual and actual differences between generations [05:34] Work disengagement and quiet quitting [08:36] The importance of promises in building loyalty[10:27] Differences between boomers, gen X, and millennials[16:52] Understanding and Treating Young Employees as Individuals[19:57] Ad Break- Learn more about our Leaders program[21:52] Embracing Lopsidedness and Sharing Failures[23:11] Moving Away from the Great Man/Woman Theory of Leadership [25:14] Improving Performance Reviews for Younger Employees [28:49] Incentivizing Teams Instead of Individuals [31:22] Mentorship vs. Advisor Relationships [34:53] Engagement and Performance Measurement [38:45] Positive Aspects of Gen Z

This week, please join author Kavita Sharma and Associate Editor Svati Shah as they discuss the article "Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction." Dr. Greg Hundley: Welcome listeners, to this April 11th issue of Circulation on the Run. And I am one of your cohosts, Dr. Greg Hundley, director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Peder Myhre: And I am Dr. Peder Myhre from Akershus University Hospital, and the University of Oslo in Norway. Dr. Greg Hundley: Well, Peder, wow. This week's feature discussion, very interesting. We spend a lot of time, especially with our colleague, Dr. Carolyn Lam, on heart failure preserved ejection fraction. But this week's feature discussion, it's going to focus on some of the myocardial metabolomics in this condition. But before we get to that, how about we grab a cup of coffee, and jump into some of the other articles in the issue? How about if I go first? Dr. Peder Myhre: Let's go, Greg. Dr. Greg Hundley: Okay. So Peder, some believe that cardiovascular disease may be the main reason for stagnant growth in life expectancy in the United States since 2010. And so, the American Heart Association, as you know, recently released an updated algorithm for evaluating cardiovascular health. Life's Essential 8, and it has a very nice score. So these authors, led by Dr. Lu Qi, from Tulane University, aimed to quantify the associations of the Life Essential 8 scores with life expectancy in a nationally representative sample of US adults. And the team included 23,000 non-pregnant non- institutionalized participants who were age 20 to 79 years, who participated in the National Health and Nutrition Examination survey, or NHANES, from 2005 to 2018. And whose mortality was identified through linkage to the National Death Index, from the period extending through December of 2019. Dr. Peder Myhre: Oh wow. So really, a validation of the Life's Essential 8. Greg, that's so interesting. What did they find? Dr. Greg Hundley: Right Peder, as you say, very interesting. So here are some of the data, and let's itemize them. So, during a median of 7.8 years of follow up, 1,359 total deaths occurred. Now, the estimated life expectancy at age 50 was 27.3 years, 32.9 years, and 36.2 years, in participants with low Life's Essential 8 scores, less than 50. Moderate, so Life's Essential 8 scores of greater than or equal to 50, but less than 80. And then, high scores, greater than 80. Okay? So equivalently, participants with high Life's Essential 8 scores had an average of 8.9 more years of life expectancy at age 50, compared to those with low scores. Next, on average, 42.6% of the gained life expectancy at age 50, from adhering to sort of that cardiovascular health, those recommendations, was attributable to reduced cardiovascular death. Next, significant associations with the Life's Essential 8 score and life expectancy were observed in both men and women. Next, similarly significant associations of cardiovascular health, Life's Essential 8, with life expectancy were observed in non-Hispanic Whites and non-Hispanic Blacks, but not in those originating from the country of Mexico. So Peder, finally, in summarizing all of this, adhering to the cardiovascular health lifestyle, defined by the Life's Essential 8 score, it was related to a considerably increased life expectancy. However, because of the findings from the individuals from the country of Mexico, more research is needed to be done in some of these minority groups, and particularly, those of Hispanic ethnicity, and perhaps other races. Dr. Peder Myhre: Oh, wow. Very interesting. And I would love to learn more about this subgroup analysis in future studies. So Greg, the next paper is about the hospitalization for heart failure measures. Because contemporary measures of hospital performance for heart failure hospitalization, the 30-day risk standardized readmission and mortality rate, are estimated using the same risk adjusted model and overall event rate for all patients. Thus, these measures are mainly driven by the care quality and outcomes for the majority racial ethnic groups, and may not adequately represent the hospital performance for patients of Black or other races. And in this study, led by co-corresponding authors, Mentias from Cleveland Clinic and Pandey from University of Texas Southwestern Medical Center, the authors used fee for service Medicare beneficiaries from 2014 to 2019 hospitalized with heart failure, in hospital level 30 day risk standardized remission and mortality rates were estimated using traditional race agnostic models and the race specific approach, with measures derived separately for each race ethnicity group. Dr. Greg Hundley: Ah, very interesting, Peder. So what did they find from this study? Dr. Peder Myhre: So the study included more than 1.9 million patients, comprising of 75% White patients, 15% Black patients, and 10% patients of other races, with heart failure from 1,860 hospitals. And compared with the race agnostic model, composite race-specific metrics for all patients demonstrated stronger correlation with 30 days readmissions. And that is correlation coefficient 0.78 versus 0.63, and 30 day mortality rate 0.52 versus 0.29 for Black patients. In concordance in hospital performance was for all patients and patients of Black race was also higher with race specific as compared to race agnostic metrics. So Greg, the authors conclude that among patients hospitalized with heart failure race specific 30 day risk standardized remission and mortality rates are more equitable in representing hospital performance for patients of Black and other races. Dr. Greg Hundley: Very nice, Peder. What a beautiful summary in a very elegant study. Peder, myocardial insulin resistance is a hallmark of diabetic cardiac injury. However, the underlining molecular mechanisms for this relationship remain unclear. Now, recent studies demonstrate, that the diabetic heart is resistant to several cardioprotective interventions, including adiponectin and pre-conditioning. The universal quote, unquote, resistance to multiple therapeutic interventions suggest, impairment of the requisite molecule, or molecules, involved in broad pro survival signaling cascades. Now caveolin is a scaffolding protein coordinating trans-membrane signaling transduction. However, the role of caveolin-3 in diabetic impairment of cardiac protective signaling and diabetic ischemic heart failure is unknown. And so these investigators, led by Dr. Xinliang Ma, from Thomas Jefferson University, studied mice fed a normal diet or high fat diet for two to 12 weeks, and subjected them to myocardial ischemia and reperfusion. Dr. Peder Myhre: Oh wow. What an interesting preclinical science paper, Greg. What did they find? Dr. Greg Hundley: Right. So the authors found that nitration of caveolin-3 at tyrosine 73 and resulted signal complex dissociation was responsible for cardiac insulin adiponectin resistance in the pre-diabetic heart. And this contributed to ischemic heart failure progression. Now, early interventions preserving caveolin-3 centered signal zone integrity was found to be an effective novel strategy against diabetic exacerbation of ischemic heart failure. And Peder, I think these very exciting results suggest that this is a new area of research and further experiments are warranted. And there's a very nice editorial by Professor Heidenreich, entitled “Pursuing Equity in Performance Measurement. Well Peder, there's some other articles in this issue, and we'll dip in this week to the mail bag, for a Research Letter from Professor Hibbert, entitled “Utility of a Smartphone Application in Assessing Palmar Circulation Prior to Radial Artery Harvesting for Coronary Artery Bypass Grafting.” Dr. Peder Myhre: That is so cool. And we also have a Letter from Dr. Kim, regarding the article entitled, “Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study.” Dr. Greg Hundley: Very nice. Well, how about we get along to one of Carolyn's favorite topics, heart failure with preserved ejection fraction, and learn more about myocardial metabolomics? Dr. Peder Myhre: Can't wait. Dr. Carolyn Lam: Today's feature discussion is on my favorite topic, heart failure with preserved ejection fraction, or HFpEF. But today, what we're focusing on is truly novel. We are looking at the myocardial metabolomics of human HFpEF, very, very valuable data and insights. We're so pleased to have with us the corresponding author of today's feature paper, Dr. Kavita Sharma, who's from the Johns Hopkins University School of Medicine, and our associate editor, Dr. Svati Shah, who's, of course, from Duke University School of Medicine. So welcome Kavita and Svati. Kavita, if I could start by, please put us and bring us all to the same level of knowledge, by perhaps explaining in simple terms, what is metabolomics? And what is normal versus perhaps abnormal metabolomics, in a known condition, like systolic heart failure or heart failure with reduced ejection fraction? Dr. Kavita Sharma: Sure. Well thank you, Carolyn, for the opportunity to chat around this topic. And it's great to be with you and Svati this morning. Metabolomics is a broad general study of essentially, all the chemical processes involving metabolites, or small molecule substrates, their intermediates, and even the products of cellular metabolism. This can be studied in really, any organ system, in any organ. What is really unique, I think, to this particular paper in our project is that, it has yet to have been defined or described in human HFpEF from the myocardial tissue. We call this heart failure with preserved ejection fraction, and inherent to that name in this complicated syndrome is that, there is something probably wrong with the heart, yet we have not really had much insight to what that might be from direct myocardial tissue. We are also still learning about what metabolomics looks like in, for example, the heart failure with reduced ejection fraction state. Though, there is more published in this space than in HFpEF. From the limited knowledge that we have, it does appear that heart failure with reduced ejection fraction hearts, and this is certainly seen in the plasma, which is where most of metabolomic studies have generated from, those hearts tend to utilize various forms of energy banks, if you will. Whether that's fatty acid oxidation, whether that is glucose utilization or intermediates and so on. And our primary interest was to understand, how do the preserved EF parts in patients fare in comparison? Dr. Carolyn Lam: Oh, thank you so much, Kavita. That was beautifully explained. And indeed, what's so special about your paper is, it's not just circulating metabolites but myocardial metabolites. And you have the control groups that are so important to study at the same time. So patients with HFpEF, but also those with HFrEF and versus controls. And thank you for establishing too, that if I'm not wrong, fatty acid metabolism accounts for the majority of ATP generation in the normal heart. Whereas, this declines a little in the HFrEF heart. And now, I think we're about to find out what happens in the HFpEF heart. So if you could explain what you did and what you find. Dr. Kavita Sharma: Yes, absolutely. So we examined, again, tissue and plasma metabolomics from 38 subjects with HFpEF. These are patients referred to the Hopkins HFpEF Clinic. And so they have been essentially, clinically evaluated, and have what we define as HFpEF, based on hemodynamic testing. So a right heart catheterization, often with exercise, that meets criteria for diagnosis of the syndrome. As you stated, we compared our HFpEF patient tissue and plasma samples to samples coming from patients with HFrEF, dilated cardiomyopathy, and non-failing controls. And the latter two sources were a tissue bank from the University of Pennsylvania, that is long-standing, where patients with endstage dilated cardiomyopathy are able to have tissue banked at the University of Pennsylvania at the time of explant prior to transplant. So albeit, we are comparing to fairly advanced end stage dilated cardiomyopathy, and control tissue comes from unused donor hearts, essentially. So presumably, normal heart function patients, likely in a brain death state, who for whatever reason, the hearts were not utilized for transplantation. Again, not an entirely perfect controlled state, but again, given the nature of the work, the fact that it's myocardial tissue, the closest that we have found we've been able to come to for a control comparison. We started out performing what we call quantitative targeted metabolomics. We measured organic acids, amino acids, and acylcarnitines in the myocardium. And that was totaling around 72 metabolites. And we did the same in plasma, so close to 69 metabolites. And our metabolomics work was actually completed at the University of Pennsylvania. And so, I wish to credit Dr. Zoltan Arany and Dr. Dan Kelly for their great collaboration in this study. Dr. Carolyn Lam: That's wonderful. Kavita, if you could tell us a little bit more about the patients with HFpEF. We understand it was end stage dilated cardiomyopathy, HFrEF, and donor hearts as the controls, but the patients with HFpEF, in relation to obesity, diabetes, and how that may impact the interpretation of the results. Dr. Kavita Sharma: Sure. So these are HFpEF patients that are in an ambulatory state outpatient setting. They have many of the comorbidities we know are intrinsic today to HFpEF. Out of our HFpEF population, the majority were women. So 71%, that's 27 out of the 38 we serve. And we're very fortunate to serve a African-American enriched population in Baltimore that's intrinsic to our center. And so, over half of our patients were Black. The remaining Caucasian, one non-Caucasian. Over half had been hospitalized, for example, in the prior one year. So these are certainly symptomatic patients. And all had NYHA II or greater symptoms. We do have a rather obese cohort at Hopkins. And so, our median BMI, for example, was 39, our mean is very similar. And the majority have, as we see often in HFpEF, the majority with hypertension, over half with diabetes. In fact, it was actually 70% or so. Rather few with coronary disease, and this is a trend we're seeing in general in HFpEF in the present day kind of common phenotypes, and about a third with atrial fibrillation. So really, representative, I think, of this kind of cardiometabolic as we call it, phenotype of HFpEF, that is the predominant phenotype we're seeing, at least in North America. Dr. Carolyn Lam: Oh, that's perfect. And then, maybe just a few words about the results before I bring Svati in for her thoughts. Thanks. Dr. Kavita Sharma: Sure, absolutely. So we conducted this study in a couple different stages. We first started with performing a principal component analysis and hierarchical clustering analysis, to see whether the myocardial metabolites and the plasma metabolites, respectively, would they distinguish these three patient groups? So HFpEF from HFrEF and controls. And interestingly, in the myocardial tissue, our PCA analysis and our hierarchical clustering analysis show that actually, in fact, as few as 70 metabolites in the myocardium really distinctly differentiate these three subgroups. The top contributors that separated HF from controls, for example, and HFrEF, were mostly related to amino acids, including branched chain amino acids and their catabolites, as well as medium and long chain acylcarnitines, which are byproducts of fatty acid oxidation. When it came to the plasma metabolome, on the other hand, there was far less distinguishing between the groups, and significant overlap, both in PCA and hierarchal clustering. And really, the take home there is that, the myocardial tissue and the plasma were really quite distinct for the overall metabolite analysis. But then, even as we broke it down by fatty acid oxidation, by glucose metabolism, and even branched chain amino acids, we saw this trend continue, that the plasma was quite distinct from the myocardial tissue. Now, which of the two is more representative of the disease state? Which is the one that we should be paying more attention to? I think that remains to be fully understood further. And of course, it would be really nice to replicate these findings in another cohort. But that is something that, I think, is a first, that certainly, that we have seen and important for the community. Dr. Carolyn Lam: Indeed. Oh, Kavita, we could go on talking forever, but I'd really love Svati's thoughts. Why was this paper so special? What does it tell us clinically with any implications? Dr. Svati Shah: Yeah. I just want to commend Dr. Hahn, Dr. Sharma, on this incredible work. If you can just imagine how much painstaking work this took for Dr. Sharma and Dr. Hahn. It's a very careful phenotyping of HFpEF. These are true HFpEF patients. The ability to get tissue, and to pair the tissue to the plasma, so that we can really understand. When we measure things in the circulation, and we think they're telling us about the heart, are they actually telling us about the heart? So I really want to commend this incredible work. And Carolyn, I love talking about cardiac metabolism, because the heart is an incredible organ, right? The heart is a metabolic omnivore. It'll eat many different kinds of fuels, and a lot of different things determine which fuels it uses. And as you nicely outlined, Carolyn, earlier, in the normal heart, the heart prefers to use fatty acids. But what we are not completely certain of is, what happens in HFpEF? So in HFrEF, we know that the heart switches to glucose, which is not a great fuel, actually. It's actually, a metabolically inefficient fuel. And so we know in HFrEF, that the heart has this metabolic inflexibility. All of a sudden, it's not an omnivore, and it's kind of stuck with certain fuels, which are not very healthy for it. But what Dr. Sharma and Dr. Hahn have shown, for the first time really, is what happens in HFpEF? And so, I think it's really cool that, actually, it just highlights how complex HFpEF is as a disease. So they were able to show that in some ways, HFpEF is similar to HFrEF, including that there's impairments in use of these fatty acids, which is what the normal heart does. But, they also show that HFpEF may be different than HFrEF in many ways, including, because of these branched chain amino acids. And that may be because of some of the clinical differences that we know exist in patients with HFpEF, including the obesity and diabetes, that Dr. Sharma nicely outlined. Although, I want to point out, they were very careful about trying to take these clinical factors into account when they looked at differences in the metabolites. So really incredible work, highlighting that the HFpEF heart also has this metabolic inflexibility. It also is not a metabolic omnivore like the normal heart is, but highlighting important differences, potentially, between HFpEF and HFrEF. Dr. Carolyn Lam: Oh, Svati, thank you for putting that so clearly. Dr. Kavita Sharma: No, I think that was a really elegant summary of the findings, Svati. And thank you for your kind words and support in allowing us to share our work through Circulation. I really couldn't say it better, but that's exactly what we seem to find is that, when we look at various sort of stores or banks of energy resource, what we really found is that these HFpEF hearts are energy inflexible, as Svati said, that begins with fatty acid metabolism. And so, when we look at, for example, medium and launching acylcarnitines, what we find is that these are markedly reduced in HFpEF myocardial tissue, quite similar to HFrEF. Again, both of them reduced compared to controls. And again, these are byproducts of fatty acid oxidation, and that is really responsible for almost 80% of generally what we think of energy metabolism in the normal state. In the plasma, however, again, back to that theme where we don't see that reproduced in the plasma, we find that HFpEF is actually not too dissimilar from controls for certain medium and long chain acylcarnitines, and then closer to HFrEF in some cases. And interestingly, we compared our metabolomics study to our prior report of our RNA sequencing paper, that was also published in Circulation now two years ago. And what we found is that, there is reduced gene expression of many of the proteins involved with fatty acid uptake and oxidation, when we compare them to control states. So the story is sort of, fits with what we have seen previously, and when we focus in on this group of genes. Our analysis of glucose metabolism though, did not include glycolysis or glucose oxidation intermediates. We still found that, majority of the TCA cycle intermediate, so succinate, for example, fumarate, malate, were all reduced in HFpEF versus control. It was really only pyruvate in isolation that was increased in HFpEF myocardium, compared to controls. And again, a number of genes implicated in glucose metabolism in general, we found to be lower in HFpEF versus control, including gluten 1, or SLC2A1, which is involved in glucose uptake. So again, this theme of, we have patients with significant obesity, many in the diabetic state, we would think that these hearts would utilize these energy stores, but they don't seem to be. And finally, we see distinct differences in the tissue and branched chain amino acid pathways as well. There appears to be some sort of a block between the branched chain amino acids, and then sort of byproducts, as you continue down through ketoacids and further. And we don't fully understand where those blocks are, but that was certainly notable. And then lastly, I'll say, one interest that we've had, and really, what led to much of this work in the tissue, is to pursue what we call deep phenotyping. Can these molecular signatures, whether it's gene expression, or metabolomics, or what we're working on now, which is proteomics, can these really help us identify unique subgroups within HFpEF? And so, we've tried to do that with the metabolomics, and we found that, using various sort of clustering analytical methods, in fact, there is significant overlap, as it turns out, within HFpEF, when it comes to the metabolomic signatures. And we only found, really, two subgroups within HFpEF. And even these two really did not have much that distinguished them, beyond branched chain amino acids. And so, this is the first time, at least that our group has seen, at a tissue level, that there is actually a fair bit of homogeneity now in the metabolomic signatures, compared to our RNA sequencing work. And that may be reflective of now, this increasingly cardiometabolic phenotype of HFpEF. And now, we may be seeing signs of that at the clinical and at the treatment level, where we have therapies like SGLT2 inhibitors, that are showing benefit to what seems to be a much broader spectrum of HFpEF, compared to prior therapies. So a lot of questions that have been generated from the work, and we're looking forward to exploring much of this in more detail. Dr. Carolyn Lam: And Svati, may I give you the last word? Where do you think this field is headed next? Dr. Svati Shah: I think there's so much to do, and I think Dr. Sharma and Dr. Hahn have highlighted how much work there is to do in this space. We're brushing the surface and understanding cardiac metabolism with this really important paper. But Carolyn, as you pointed out, we really need to understand what happens to these patients over time? What happens to, not just cardiac metabolism, but molecular biology more broadly, in patients with HFpEF with these various treatments? Including now, thank goodness, we have SGLT2 inhibitors as a therapeutic intervention for patients with HFpEF. And in fact, we published in Circulation a few months ago, a paper led by a very talented junior faculty, Senthil Selvaraj, where we actually showed that these acetylcarnitine levels that reflect fatty acid oxidation actually are changed by SGLT2 inhibitors, and are associated with changes in clinical outcomes in HFpEF. So we really need larger sample sizes, being able to look at these patients in a longitudinal fashion. But really, doing what Dr. Sharma and Dr Hahn have done, which is careful, careful phenotyping and multidisciplinary teams, so that we can understand the molecular biology, as well as the clinical implications. Dr. Carolyn Lam: Oh, wow. Thank you so much, Kavita and Svati, for this incredible interview. I learned so much, and enjoyed it so thoroughly, as I'm sure our listeners did as well. Well, listeners, you've been listening to Circulation on the Run. Thank you for joining us today, and don't forget to tune in again next week. Dr. Greg Hundley: This program is Copyright of the American Heart Association 2023. The opinions expressed by speakers in this podcast are their own, and not necessarily those of the editors, or of the American Heart Association. For more, please visit ahajournals.org.

Welcome to the Aphasia Access Aphasia Conversations Podcast. I'm Ellen Bernstein-Ellis, Program Specialist and Director Emeritus for the Aphasia Treatment Program at Cal State East Bay and a member of the Aphasia Access Podcast Working Group. AA strives to provide members with information, inspiration, and ideas that support their aphasia care through a variety of educational materials and resources. I'm today's host for an episode that will feature Davetrina Seles Gadson. We'll discuss her work involving how brain lesion characteristics may intersect with aphasia recovery, race, and psychosocial factors, as well as issues involving health-related quality of life assessments. Dr. Davetrina Seles Gadson is the first Black-American to graduate with a Ph.D. in Communication Sciences and Disorders from the University of Georgia. She is a neuroscientist and certified speech-language pathologist with expertise in adult neurological rehabilitation and patient-centered outcomes. She currently is Research Faculty, in the Department of Rehabilitation Medicine, at Georgetown University. Dr. Gadson's research focuses on the influence of health disparities in minority stroke survivors with aphasia and the effect of such disparities on brain functioning, aphasia severity, and health-related quality of life. Most rewardingly Dr. Gadson is the co-host of “Brain Friends”, a podcast for neuro nerds and stroke survivors to talk about aphasia advocacy, language recovery, and community. Listener Take-aways In today's episode you will: Learn how health disparities may influence aphasia outcomes and why more research is needed   Discover why "Brain Friends" is another podcast you'll want to add to your playlist.   Gain practical tips on how to build confidence in intercultural interactions with your clients   Hear how health-related quality of life (HRQL) measures can help  inform your clinical practice   We'd like to recognize Kasey Trebilcock & Amanda Zalucki, students in the Strong Story Lab at CMU, for their assistance with this transcript. Show notes edited for conciseness Ellen Bernstein-Ellis (EBE) EBE: I am so excited to have a fellow podcaster here today. Thank you for being here. And I just listened to the January Brain Friend's episode. It was great. So I hope our listeners will check it out too. I want to also give a shout out to your consumer stakeholder and co-podcaster, Angie Cauthorn, because she was a featured guest on episode 70, in June of 2021, as we recognized Aphasia Awareness Month, and you just spoke with her about aphasia types and aphasia conferences, and you gave a big shout out to CAC and you gave clinical aphasiology conference and you also gave a big shout out to the Aphasia Access Leadership Summit. So really important conferences, I think that stimulate a lot of discussion and values around patient centered care. And your Brain Friends podcast just has a great backstory. So why don't we just share about how that all started? Where's the backstory to that, Davetrina? DAVETRINA SELES GADSON: Thank you so much for having me. This is such an exciting opportunity. So, Brain Friends started with myself and Angie. We were on the National Aphasia Association's Black Aphasia group call and I just loved her energy. She reached out to me after we finished that group call, and we just started talking. Our conversations were so informative, and it just lit this passion and excitement in me. I said, “Hey, can I record some of these, and maybe we do like a podcast?”, and she was totally down for it. It's just been such an innovative and fun way to disseminate science and engage many stakeholders. EBE: I want to thank Darlene Williamson, who's president of the National Aphasia Association for sending me a little more information. You told me about this group, and so I wanted to find out more. She provided this description by Michael Obel-Omia and his wife Carolyn, and I hope I said his name correctly, who provide leadership to this group. And they said that in this group, the Black American Aphasia Conversation group, “provides a place for Black people with aphasia to share their stories, provide support, meditation, and brainstorm ways to advocate and consider policies. We will discuss the unique challenges and gifts we share due to our experiences with disability and race.” I found out that you can reach out to the National Aphasia Association (NAA) for more information and to get on the email list for a meeting notifications. And in fact, I put the registration link in our show notes today. So, sounds like that group has been a meaningful discussion forum for you, too. SELES GADSON: It's been so fun. I share how for me, I've been in the field practicing for a little over 16 years now, and this was my first time being in a room with so many people that look like me. And for many of the survivors on the call, I was one of their first Black SLPs that they had ever met. Just even having that connection, and being able to speak to some of the challenges, and some of the things culturally that we both share has been my outlet, biweekly. EBE: I'm going to make sure we have that link in our show notes. Also, the link to your podcast because I encourage people to listen to Brain Friends, I've really enjoyed it.  When you and I were planning for this episode today, you talked about how being part of the National Aphasia Association's Black American Aphasia Group really helped to energize you and the research you were doing, and what a nice integration of life that was. I will want to tell our listeners about one more wonderful thing, and that's the interview you were part of on the ASHA Voices podcast as well as the related article in the ASHA leader, where I learned more about your journey to doing this research. So, as you provided clinical services for a Black client as an outpatient clinician, and this is pre- doctoral research, you recognized that there was a significant gap in the literature around working with African Americans with aphasia. You saw the need to understand the impact of aphasia on identity and motivation in order to best help this particular client. And those are both really important concepts within the Life-Participation Approach to Aphasia (LPAA) framework as well. So, then you shared that you got some important advice from an important mentor. Do you want to share what happened next? SELES GADSON: Definitely. So, one thing that's also unique about that time is that at that point in my career, I had worked in many of the clinical settings. I had done acute care, inpatient rehabilitation, skilled nursing facility, and even worked as a travel SLP traveling throughout the United States. And so, once I had got to that outpatient setting, it was different from any of the other settings because these individuals were home. And often times, they wanted to get back to work. I remember feeling a little discouraged because I wasn't finding research on a lot of functional treatment approaches or functional therapy. In addition, I wasn't finding research on black stroke survivors with aphasia. And so, I mentioned to one of my mentors at the time, Dr. Paul Rao. I said, “what's going on in the field? And I'm not seeing this, and I have this client, and I don't really know what to do.” And he said to me, “Stop complaining kiddo, and go back and get your PhD.” Admittedly, when he said it, it was kind of like, “okay fine, I'll go do it.” I don't think I realized all what it would take. That's what really made me pursue the degree was this notion that I could help facilitate some of that change and bring some of the research that I needed to see. EBE: That is so important. And that story really made me reflect on another story that has really impacted me from a dear colleague, because you experienced in your doctoral work some concerns about doing research on Black Americans because your interest was seen, as it said in I think the ASHA Voices interview or in the Leader, as “personally motivated.” Your story mirrors one that a colleague and dear friend, Nidhi Mahindra, told me as well. During her doctoral research, she was told that while pursuing multicultural interests were worthy, that she may face barriers to getting funding to pursue that line of work. That might be problematic, right? She had to struggle with that. Despite that daunting message, she persisted, and then was funded by ASHA on a grant studying barriers influencing minority clients' access to speech pathology and audiology. Nidhi reminded me how our life experiences can often inform our work in important and valuable ways. Davetrina, you've channeled your experiences into these explicit observations and data that you shared with your doctoral committee. That was a really important part of moving forward.  Do you want to share some of the points  gathered for that doctoral committee to help support why this research is so important? SELES GADSON: First, I want to thank Nidhi. Hopefully I'm pronouncing her name right, for her perseverance, because it was some of her work that helped me in my dissertation. Being able to cite her just really shows the importance that everybody plays in breaking barriers and pursuing the things that really speak to them. And one of the things that I'll clarify, it was two parts in pleading this case. The first part was that I changed the committee. I think that that was a supportive thing. And then, the second part was that when I prepared all of the research on why I needed to do this work. Some of the research looked at what we knew already with stroke recovery in minoritized groups, which was that Black African Americans were twice as likely to have a recurrent stroke than any other ethnic group and what we were seeing in the aphasia literature for Black Americans, which was the narrative of Black Americans having longer hospital stays, more hospital costs, but poor functional outcomes. And so, it was these two key pieces that I had really gathered. When I went back to the new committee to share and plead my case on why I really wanted to do this research, they had that initial onset of knowing that this research definitely needs to be done. I think that that's what helped it go through. EBE: Wow. I think those are really important reasons. That whole concept of allowing our life experiences to inform our work and to value that. As we start to talk about your research, and I'm really excited to get to share this amazing work you're doing, I thought it might be helpful to define some of the terms that are integral to this research Some of the definitions are a little tough to wrap your arms around because they're not consistent in the literature or are still waiting to develop. Let's start by discussing what you want the listeners to know about the definition for health-related quality of life, or, as we'll call it, HRQL. SELES GADSON: HRQL is operationally defined that it's multi-dimensional. The way I define it a lot in my work is the perception of the individual's ability to lead a fulfilling life in the presence of a chronic disease or disability such as aphasia, but really their perception in five domains. The five domains that I look at in my work are physical, mental, emotional, social communication, and then role, the individual's ability to get back into the activities that they used to be able to do. EBE: Okay, that's really helpful. I think we should also discuss or define patient-reported outcomes or PROs. Sometimes they are also referred to as PROM's, patient-reported outcome measurements. How do they relate to HRQLs? SELES GADSON: Patient-reported outcomes is a health outcome directly reported by the patient without interpretation. Patient-reported outcomes often look at the status of the health condition. The biggest thing about patient-reported outcomes is that it's without the interpretation of the practitioner. So, whatever the patient says is what we're going to take as gold. EBE: Why is it particularly important then to look at HRQOL for Black stroke survivors? SELES GADSON: That's such a great question. And so I want to break it down in two parts. I think the first part is that given the lack of normative data for Black stroke survivors, when we're only looking at clinician-reported outcomes, that's where we get to this bias and the normative bias. I know that there's research out where there are some outcomes to where we're already seeing this five-point difference. And for some research, that five-point difference is considered clinically meaningful. I think that if we're not using these patient-reported reported outcomes, then we put ourselves in a position to contribute to the disparities that we're seeing in standardized assessments. So that's the first answer. The second reason is that we know that nonclinical factors such as physician-race concordance drive up to 80% of what we're seeing in poor functional outcomes in minoritized groups. If we're not asking the person, then we're not able to really understand the things that they want to do, and we're already coming in with this majority type attitude which could influence one's participation in therapy. The last thing that I think is most important, whether you're Black, white, purple, whatever, is that we have these insurance demands that sometimes may not allow us to get to all the things that we may see from an impairment base. By using the patient-reported outcomes, we are helping structure therapy in ways that matter most to the patient. EBE: Well, that reminds me of this amazing quote that I was hoping I could work in today. I circled it in big yellow pen when I first read through your research. You said that it's really important because, due to the lower HRQL that we find in individuals with aphasia, it's “imperative that the development of a treatment plan incorporates what the patient prioritizes. And it's imperative that clinicians have a way to measure these subjective attributes to make a meaningful impact on care.” That's what we want to do. SELES GADSON: So important, because I think what we have to realize is that part of our role as the practitioners providing this skilled intervention, is really helping the individual get back to what they want to do. And I think that if we're not asking them what they want to do, then we're not really able to structure therapy in matters that mean the most to them, but also help them to start to recognize that as part of this identity with aphasia, that there's this new normal for them. Sometimes, individuals are going to rate themselves based off of what they used to be able to do. But if they know that one of their goals was to be able to talk on the phone, or to play bridge with their friends, and we worked on that in therapy, they're now able to look and see, before I scored my telephone confidence at a 50. Now I feel like I'm at a 90, and so sometimes that own self-recognition can support motivation, and can even support therapy, once insurance dollars run out. EBE: I really appreciated doing this deeper dive into PROs as I read through some of your research. And one of the resources I came across was a really interesting table that talked about six categories of PROs. And I'll put a link in the show notes to a 2015 book by Cella, Hahn, Jensen and colleagues called “Patient-Reported Outcomes and Performance Measurement.” (They list six different kinds of PROs in a helpful table.) But the main category that your work is utilizing is actually these HRQL measures. You've been stating why it's so important. HRQL PROs help to frame diagnostics and treatment because you're trying to prioritize what the patient wants and needs-- what they're expressing. SELES GADSON: Right, exactly. I think that one of the things that it's really important for practitioners to understand, is that these things are mandated by what we see in our scope of practice. When I say mandated, I mean we are called to reduce the cost of care by designing and implementing treatment that focuses on helping the individual. If we're not asking the individual what they want to get back to, then I think that we're putting ourself at a position that makes it more challenging to serve in that way. EBE: One of the things we like to do on this podcast is to provide resources that will help clinicians think differently or do something differently tomorrow as they meet face-to-face with their clients. And one of the things I thought we'd put in our show notes is a link to the PROMIS website, because that was something you've used in your research. Do you want to explain a little bit about that website? SELES GADSON: One of the things that I like about the PROMIS website is that it has a list of health outcomes available to use for a range of individuals-- for pediatrics, for adults. I like that it's free, most of them, and I think that it's a good place to start. Some of the outcomes on that website are also even appropriate for in acute care, meaning that they may not take a long time to administer. And so, I think that that's a good place to start. EBE: Well, thank you. And I want to move right into this wonderful paper where you are co-author with Wesley, van der Stelt, Lacey, DeMarco, Snider, & Turkeltaub, that looked at how brain lesion location interacts with HRQL. Can you share a couple key takeaways from that paper?  I hope you'll highlight the one related to depression and HRQL. We're having a lot of research right now around the emotional impact of aphasia and how that will impact recovery outcomes as well. So, tell us a little bit more about that work. SELES GADSON: We looked at the domains of health-related quality of life associated with specific deficits and lesion locations in chronic aphasia. We examined the relationship between HRQL using the Stroke and Aphasia Quality of Life Scale by Hilari and her colleagues, as well as a depression scale, and different impairment-based measures---our battery that we used here. What we found was that language production and depression predicted communication HRQL, meaning that those individuals that reported lower communication HRQL also had a significant depression associated with it. We did lesion symptom mapping in this study. Basically, what we were looking at is to see if HRQL mapped on to discrete areas of the brain. We found that individuals that reported lower psychosocial HRQL had inferior frontal and anterior insula lesions; where individuals who reported lower physical HRQL had lesions in the basal ganglia. This confirmed for us that even though HRQL is this subjective perception, we were seeing it map on to these very specific areas in the brain that also predicted some of the impairment measures that we know of. EBE: That can get us to start thinking about if we have patients with these types of lesions, maybe to be more on the alert for depression. I think that's one point you made. But you also mentioned another important takeaway in the study about the impact of depression on HRQL related to the training of SLPs. This all ties together. What are your thoughts there? SELES GADSON: I think that when we are recognizing that individuals with aphasia are experiencing a new normal, and I think that the research has been very clear on understanding that depression does relate to and contribute to one's communication. I think that there is an opportunity for speech-language pathologists to have more counseling classes. And again, make sure that we're tapping into what the patient wants to do in order to hopefully help mitigate some of those feelings of depression. EBE: I really endorse building those counseling skills in our graduate programs for our students, so they go out feeling more confident and more skilled and knowing that that is going to be an ongoing journey as a speech-language pathologist to build that skill set. SELES GADSON: And shameless plug, I think our episode six of Brain Friends is a mental health episode. I have one of my good girlfriend colleagues there who is a counseling psychologist. She shares with us helping skills for the practitioner, and we share on that episode10 skills that you can do as a clinician to support the person with aphasia. EBE: Thank you for sharing that. That's really important. And again, the link to Brain Friends will be in our show notes. Let's take a moment and talk about how you connect this finding about depression to the role of social communication, because you said it was those scores that were down in your measure. SELES GADSON: With that particular study or overall? EBE: However you'd like to discuss it. I'm opening that door to you. SELES GADSON: One of the things that we were seeing is that individuals were reporting the depression within this Communication HRQL domain. So even though we didn't dive into it too deep in this study, it was more of the correlation and recognizing that individuals that were reporting this higher level of depression, also have this higher level, or this lower report of communication HRQL, making those links specifically. I do have something that I'm working on right now, that will completely answer that question a little bit more solidly. I don't want to speak too much on this, so stay tuned. EBE: Absolutely staying tuned, there's no question. You also had another article that I found intriguing-- An article with your coauthors, Wallace, Young, Vail, and Finn, a 2021 article that examined the relationship between HRQL, perceived social support, and social network size in Black Americans with aphasia. And that paper highlights that there's been little research exploring HRQL in Black Americans. Of the five factors that comprise HRQL, why did you decide to focus on social functioning? And specifically social support and social network in this study? SELES GADSON: Well, that really came from the literature. One of the things that the literature said is that we knew that social HRQL contributed in some way, but we weren't sure what way. And we weren't sure what pieces of social functioning contributed. My apologies to the researcher who said it, but it set me up perfect for my dissertation work to say, “this is why I'm looking at social functioning in these two specific pieces,” because we didn't know. Was it social participation? Was it social network? Was it social support? That was one of the reasons why I wanted to pull out those two specific pieces. The other thing that was really important about this work was that it was the first study that really looked at what HRQL looked like in Black stroke survivors. We didn't know any of that. And so for me, it was really important to compare Black stroke survivors to normal aging Black individuals because I feel that for us to really get baseline understanding of what some of these factors are and how individuals respond in recovery, we have to compare them to their norm, or to other members in their community that look like them before comparing between Black and white or any other ethnic groups. This study is where we found that in terms of HRQL, the main difference between stroke survivors with and without aphasia and in our normal aging individuals, was that communication was the impairment. And then, with the social network and social support, we weren't seeing a difference between this homogenous group of Black people in those areas. EBE: That takes me to my next question, your research noted that the Black survivors with and without aphasia, have smaller social networks compared to white stroke survivors. That's the data that we have based on that social network data. Even though you weren't trying to compare in this study, per se, you still made sense of that finding-- trying to make sure that we don't make assumptions, and instead look at different factors that could be at play. How did you make sense of that finding, the smaller network? SELES GADSON: It was two things that allowed us to make sense of that finding. One was recognizing that in both groups, the stroke survivors with aphasia and our normal aging individuals, that because they were age matched, it could have been a factor of age--meaning that the individuals receiving the support quality and then their network, everyone was kind of in the same age group, and so, it was more of a factor of time of life versus actual culture. But then a lot of that came through in some of the anecdotal reports, and things that we even circled on the scale that we used--we use the Lubben Social Network Scale. With some of those questions, one might be how many people do you feel comfortable sharing personal details with? And often times, we got this report of “just my husband”, or “only God”. And so, we were seeing that some of this really related to the traditional and cultural values in Black Americans, where you're not going to share a lot of stuff with a lot of people. You have your set group, your small network. And that's okay. That doesn't mean that you're isolated.  EBE: I think another point you make, and maybe even thinking back to the ASHA Voices Podcast, why it's particularly important to target social communication. That is yet another life participation core concept. Do you want to speak to that for a moment? SELES GADSON: I think the thing that we have to realize with social communication is that individuals, especially within the black community, they are social, they want to talk, they want to get back to doing and interacting with their community. And so, one of the things that that looks like is maybe being able to participate again in Bible study or being able to stand up and read a scripture. And the only way that you know that, is by asking them that on a patient-reported outcome. I think that that's where that social communication piece is coming in. One of the things that I'm seeing with the Black aphasia group is that moment, that hour, where everyone is together, it's amazing. It's them using social communication. You spoke about how I said that that energized my research, and that was why--because I was on this call, and they were speaking about these things, that sometimes I feel like I have to explain to the powers that be why social communication or the LPAA approach is important. But here I was talking with all of these survivors, and they were telling me, I want to be able to communicate, I want to be able to do these things. It just really confirmed for me that this type of research, we were on the right path. EBE: Right. And this is my chance for a “shameless plug” because of my life work, and that is just the power of groups. The power of groups is amazing. SELES GADSON: You know, your life work and... EBE: Well, we don't want to go there, this episode is about you. SELES GADSON: Okay. I'm telling you; I'll get into just how influential your work has been, even when I was working as a practitioner and doing group therapy, it was your work and your research that I was going to. EBE: Well, I had the honor of getting to work with Dr. Roberta Elman, and starting the Aphasia Center of California and doing that initial research, that has been such a gift to me, so, but thank you, back to your work now. That's a great transition, because I'm going to bring us to your 2022 study, looking at how aphasia severity is modulated by race and lesion size in chronic survivors. That was an amazing study. I'm going to read another quote here from that study. And that is, “understanding the origin of disparities in aphasia outcomes is critical to any efforts to promote health equity among stroke survivors with aphasia.” You said this work led you to an “Aha!” moment. And I'd love for you to share more about that moment, and about this study. SELES GADSON: Yes, this was one of my babies, I would say it was definitely a labor of love. And it's been well received. One of the things that led us to this study was that we were already aware of what the research was saying, in regards to the narrative of Black stroke survivors having these lower scores, they were having poor functional outcomes, longer hospital stays. I really wanted to understand what components neurologically, were playing into that. The research has shown that Black Americans often may have a larger stroke due to a myriad of factors-- delayed hospital arrival, not being able to receive TPA. But I wanted to know what factors neurologically were contributing to what we were seeing, not only in this baseline difference that we were seeing, but what was the bigger picture essentially. What we found was that when we looked at race and lesion size, when we did an interaction of race and lesion size, that Black and white survivors with small lesions performed similarly. But larger strokes resulted in more severe aphasia for Black people, than white people. And that was something that we didn't quite understand, because if you think about it, the larger the lesion, the poorer your aphasia should be. But in this case, the larger the lesion, the white stroke survivors were performing better and so we offered two reasons for that. One was the potential assessment bias-- that maybe with the larger stroke, there was this code-switching element that the Black stroke survivors just weren't able to do. And we were seeing that in the larger strokes, and it wasn't being picked up in the smaller strokes. Then the other was the disparity that I had mentioned earlier, which is that access to rehabilitation. It might have been more evident-- we were seeing some of those disparities in the larger strokes. We know that individuals that come from higher earning SES groups have greater access to rehabilitation services like speech and language. That was our other reason, that we were wondering if that's why we were seeing that outcome. EBE: This reminds me some of the research that Dr. Charles Ellis has been doing. I attended his keynote speech at the IARC conference in 2022 that talked about understanding what is happening upstream, because it's going to impact what's happening downstream. In terms of health disparities, it's going to have an impact. I think your research supports that. We need to learn more about it and do the research you're doing. As you reflect on your findings across these amazing studies, this research that you've been doing, can you offer to our listeners some tips on how to have more confidence with intercultural contact? SELES GADSON: That's a great question. I think the first thing that that you have to do is put yourself in places where you are connecting with people that don't look like you. EBE: I agree. And that can be hard and challenging to do. SELES GADSON: It can be, but one of the things that I say is that it goes back to some of the things that Dr. Ellis has talked about, which is being intentional. That might mean going to a different side of the neighborhood to support a Black owned business, and being within that space, to feel how it feels to be around different cultures. The other thing that I think is really important, and it comes out of literature that looks at reducing racial bias in health care, which is to avoid stereotype suppression. So oftentimes, people may be thinking something and they don't want to share it, or they try to suppress it. And the reason why that's negative is because stereotype is a cognitive organization strategy that we use. And where it becomes negative is that if you're having these stereotype ideas, or you're just not sure, if you're not able to express them within a space that you feel comfortable with, then you suppress them. And then it kind of comes out in therapy. And so, I think that those are two huge things. And then the last thing that I would say is that it's really important to build partnerships. And so, building partnerships, either with local churches, within the university area, or just seeing how you can serve in order to help create some of that confidence. But you have to put yourself out there and not wait until therapy day. EBE: Wow, thank you for those tips. And one of them reminded me of something, a tip that a local educator suggested that, even if you don't feel like you're in an environment where your everyday social context might put you with people who look different from you, that you can still listen to other voices by listening to podcasts, sign up for podcasts, sign up for Twitter feeds of people with different voices, so you can start being present to that conversation. So that was something that I have found useful and really good advice as well. SELES GADSON: So true. The other thing that I did, even someone who identifies as a Black American when I was doing my dissertation work, and previously before some other things in my career, I noticed that perspective taking was a huge piece--putting myself or imagining myself in the individual's shoes. And so, for me, that meant that I went to Black museums and exposed myself to different cultural experiences. I wasn't going into some of these spaces, whether it was collecting data or even working with individuals from other earning communities, with some type of privilege. So even in that sense, I wanted to make sure that I checked my privilege as well by doing that perspective taking. EBE: Thank you,. And this discussion could keep going, but I know our time is getting tight here. This whole effort that you put in your research of looking at HRQL measures reminds me of some of the work that I've really admired by Hilari and you had a wonderful story you could share about her, your interaction and your use of her work. Would you like to share that quickly? SELES GADSON: Oh, she's so awesome. I was sharing how when I first was diving into this literature, her work was one of the pieces that I found, the Stroke and Aphasia Quality of Life Scale. I reached out to her and she shared this scale. And a couple of years later, I attended the International Aphasia Rehabilitation Conference in London. And she sat down with me. I asked her if she had any time, if we could just talk, and she was so welcoming. We sat down, and she might not even remember this, but even in that moment of us being able to talk about these things that we were both so passionate about, she just really spoke to me and encouraged me. And it's so funny, because now as I publish and do different things, my mom always says, “you gonna be just like Dr. Hilari.” EBE: Let's just do a shout out for mentorship, for people who take the time, and feel committed and passionate. Again, we're using that word again today, passionate, to support the new voices that are coming into the field. So that's the gift of mentorship. And in this whole discussion, you and I also talked about how important it is to be inclusive, and we talked about how HRQL measures sometimes are harder to use with people with severe aphasia and how they can get excluded from research. It's hard enough to get people with aphasia into the research, right? There's work by Shiggins and her colleagues looking at how often people with aphasia are excluded. But you made a good point about ways that we can include people with more severe aphasia. Do you want to mention that? SELES GADSON: I think one of the things that we have at our fingertips, and we know just from our training, is to use different visual cues to support those individuals that might have more severe aphasia. One of the things that we highlighted in the 2020 paper looking at the psychometric properties of quality of these patient reported outcomes, was that there are certain assessments that are perfect for individuals with severe aphasia, assessments like the Assessment for Living with Aphasia (ALA), because it has the pictures available and it has simple language. Just recognizing that even by using some of these compensation tools, whether it's pictures or modifying the language, we can still get the individual's perspective of what they want in therapy just by using some of these modifications. EBE: This reminds me, I can put one more link and resource into the show notes, because the Center for Research Excellence in Aphasia offers this wonderful speaker series. And there was just an excellent recent session by Dr. Shiggins on including people with aphasia in research. So, I'll put that link in. I want everybody to listen to that presentation. And finally, as our closing question for today, Davetrina, if you had to pick only one thing we need to achieve urgently as a community of providers, of professionals, what would that one thing be? SELES GADSON: I think we have to start using patient-reported outcomes. I think that if you were doing a clinician-reported outcome to assess the impairment, paired with that has to be some level of patient-reported outcome that will give you insight into what the patient wants to do. It's no longer optional. I think that we have to make it a paired thing with our clinician-reported outcome, is getting the perspective of the patient. EBE: I so agree with you, thank you. Thank you for this wonderful interview today. I really, really appreciate it. SELES GADSON: Thank you. EBE: And I want to thank our listeners for listening today. For references and resources mentioned in today's show, please see our show notes. They're available on our website, www.aphasiaaccess.org. And there, you can also become a member of this organization. Browse our growing library of materials and find out about the Aphasia Access Academy. If you have an idea for a future podcast episode, email us at info@aphasiaaccess.org. For Aphasia Access Conversations, I'm Ellen Bernstein Ellis and thank you again for your ongoing support of aphasia access. References and Resources Brain Friends Podcast: https://www.aphasia.org/stories/brain-friends-a-podcast-for-people-with-aphasia/ https://www.facebook.com/groups/1563389920801117 https://open.spotify.com/show/5xgkrhUhEIzJgxpRXzNpBH   Centers for Disease Control and Prevention (CDC) HRQL website: https://www.cdc.gov/hrqol/concept.htm     National Aphasia Association  Black American Conversation group registration: The Black American Aphasia Conversation Group meets through Zoom every other Monday at 4:00pm EST (1:00pm PST) . If you are interested in joining this group, please complete the form https://docs.google.com/forms/d/e/1FAIpQLSfJN9VWjrujhebT8Z48bqDZePOHYotipFC34S8T0X8_o8rG-g/viewform Patient Reported Outcome Measurement System (PROMIS) https://www.promishealth.org/57461-2/   Cella, D., Hahn, E. A., Jensen, S. E., Butt, Z., Nowinski, C. J., Rothrock, N., & Lohr, K. N. (2015). Patient-reported outcomes in performance measurement. . Research Triangle Park (NC): RTI Press; 2015 Sep. Publication No.: RTI-BK-0014-1509ISBN-13: 978-1-934831-14-4  https://www.ncbi.nlm.nih.gov/books/NBK424378/   Gadson, D. S., Wallace, G., Young, H. N., Vail, C., & Finn, P. (2022). The relationship between health-related quality of life, perceived social support, and social network size in African Americans with aphasia: a cross-sectional study. Topics in Stroke Rehabilitation, 29(3), 230-239.   Gadson, D. S. (2020). Health-related quality of life, social support, and social networks in African-American stroke survivors with and without aphasia. Journal of Stroke and Cerebrovascular Diseases, 29(5), 104728.   Gadson, D. S. (2020). Health-related quality of life, social support, and social networks in African-American stroke survivors with and without aphasia. Journal of Stroke and Cerebrovascular Diseases, 29(5), 104728.   Gadson, D. S., Wesley, D. B., van der Stelt, C. M., Lacey, E., DeMarco, A. T., Snider, S. F., & Turkeltaub, P. E. (2022). Aphasia severity is modulated by race and lesion size in chronic survivors: A retrospective study. Journal of Communication Disorders, 100, 106270   Gray, J. D. (2022). Transcript: ASHA Voices: Confronting Health Care Disparities. Leader Live. https://leader.pubs.asha.org/do/10.1044/2021-0902-transcript-disparities-panel-2022   Law, B. M. (2021). SLP Pioneers Research on Aphasia Rehab for African Americans. Leader Live https://leader.pubs.asha.org/do/10.1044/leader.FTR4.26092021.58   Lubben, J., Gironda, M., & Lee, A. (2002). Refinements to the Lubben social network scale: The LSNS-R. The Behavioral Measurement Letter, 7(2), 2-11.   Shiggins, C., Ryan, B., O'Halloran, R., Power, E., Bernhardt, J., Lindley, R. I., ... & Rose, M. L. (2022). Towards the consistent inclusion of people with aphasia in stroke research irrespective of discipline. Archives of Physical Medicine and Rehabilitation, 103(11), 2256-2263.   Shiggins, C.  (2023) The road less travelled: Charting a path towards the consistent inclusion of people with aphasia in stroke research.  Aphasia CRE Seminar Series  #36 (Video) https://www.youtube.com/watch?v=sqVfn4XMHho

Authentisches Auftreten, eine enge Community und eine Menge Engagement - alles Dinge, die einen Influencer auszeichnen. Aber wie können Unternehmen das für sich nutzbar machen und Personen des öffentlichen Lebens mit in ihre Kampagnen einbeziehen? Zusammen mit Silvia Lange, CEO von hi!share.that!, geht es heute um das große Thema Influencer Marketing, dessen Herausforderungen, Nutzen und Messbarkeit. Themen: [1:45] Was ist Influencer Marketing? [6:59] Herausforderungen im Influencer Marketing [16:18] Kampagnen-Beispiel “KaufDA” [23:18] Influencer vs. Affiliate-Marketing [31:35] Performance Measurement [39:13] Learnings und Takeaways In der Show erwähnt: hi!share.that!  kaufDAlicious: Das erste Influencer-Kochduell von kaufDA  Feedback? Gerne an podcast-dach@hubspot.com  Mehr über uns unter: https://www.hubspot.de/podcasts/listen-and-grow

Episódio da Série Ciência Aberta, conversando sobre o paper publicado no periódico Sustainability - Performance Measurement Model for Sustainability Assessment of the Swine Supply Chain. Pesquisadora: Profa. Dra. Silvana Dalmutt Kruger (UFMS). Apresentadora: Vitória Resende Freitas (Graduanda em Letras/UnB). Autores do paper: Silvana Dalmutt Kruger (UFMS); Antonio Zanin (UFMS); Orlando Durán (Pontificia Universidade Católica de Valparaíso - Chile); Paulo Afonso (Universidade do Minho - Portugal) Link: https://www.mdpi.com/2071-1050/14/16/9926

Mark Elliott, Director of Performance Measurement & Attribution Solutions at SS&C, shares his insights on ways to elevate performance measurement and attribution in this podcast. The 20-year veteran expert discusses our client profile, the common performance measurement challenges they face, and best practices to resolve those challenges. Handling the onslaught of data amidst accuracy and timeliness demands Moving from reactive, laborious processes to real value-adding activity Tailoring performance attribution to your firm's distinctiveness Communicating with and enabling stakeholders For more information, visit https://www.ssctech.com/solutions/products-a-to-z/sylvan.

First on this episode of Inside Health Care, we discuss Health Equity in an interview with Darrell M. Gray II, MD, the first Chief Health Equity Officer for Elevance Health. The company, as announced in Fall 2022, was one of 9 companies to earn distinction in both of NCQA's Health Equity Accreditation programs. This interview is one of three podcast interviews conducted in coordination with Elevance Health and was recorded live at NCQA's first Health Innovation Summit in November 2022.We then discuss antibiotics stewardship with Dr. David Hyun, who directs the Pew Charitable Trust's antibiotic resistance project. The interview, conducted alongside NCQA's Assistant Vice President for Performance Measurement, Dr. Sepheen Byron, coincides with National Antibiotic Awareness Week. Later in the program, we offer "Fast Facts" on growing concerns for antibiotic over-prescription as well as details on NCQA's Antibiotic Stewardship Program, which includes an incredible How-To Toolkit.

On this episode of Inside Health Care, we help observe the Lung Cancer Awareness month of November with a talk on advances in lung cancer screening. This interview, recorded at our Inside Health Care podcast center at the 2022 Health Innovation Summit, is sponsored by AstraZeneca.Dr. Raymond Osarogiagbon is the Chief Scientist at Baptist Memorial Healthcare Corporation, headquartered in Memphis, Tennessee. He is Director of the Multidisciplinary Thoracic Oncology Program and the Thoracic Oncology Research Group at the Baptist Cancer Center, and Principal Investigator of the Baptist Health System/Mid-South Minority-Underserved Consortium NCORP. Dr. Osarogiagbon's research interests center around improving population-level outcomes of cancer care by improving care delivery systems and processes.For training regarding lung cancer screenings, here are a few offerings to mention. First, as part of our 2022 Quality Innovation Series, NCQA offers the on-demand course titled “The Importance of Lung Cancer Screening”, led in part by our Vice President for Performance Measurement, Dr. Mary Barton.In addition, consider these two webinars from the Academy of Oncology Nurse and Patient Navigators. One is from September 2022, titled “The Role of Oncology Nurse Navigators in the Implementation of the Updated Lung Cancer Screening Guidelines.” The other, released October 31st of 2022, is “Navigating the Updated Lung Cancer Screening Guidelines: The Role of Oncology Nurses and Nurse Navigators in the Implementation of a Lung Cancer Screening Program”.Then we hear another interview recorded live at the Summit. This talk with Dr. Juan Espinoza discusses topics in and around the panel he co-hosted, titled “Digital Reshaping of the Diabetes Health-Care Ecosystem”. He appeared alongside, among others, Dr. Osagie Ebekozien, whose interview is posted as episode 7 of our limited series, “A View from the Summit”. Juan Espinoza, MD is a pediatrician at Children's Hospital in L.A., where he focuses on developing medical devices, health information systems, and patient-generated health data. The guiding principle of Dr. Espinoza's work is that data and technology have the potential to narrow the health gap faced by under-served communities all over the world.Later in our "Fast Facts" segment, we give you quick stats from the CDC on Lung Cancer prevention.

The CPG Guys, PVSB and Sri are joined in this episode by Claire Wyatt, Head of Business Strategy & Marketing Science at Albertsons Media Collective, the retail media arm for Albertsons Companies.Follow Claire Wyatt on LinkedIn at:  https://www.linkedin.com/in/clairewyatt/Follow Albertsons Media Collective on LinkedIn at: https://www.linkedin.com/company/albertsons-media-collective/Follow Albertsons Media Collective online at: http://albertsonsmediacollective.comClaire answers these questions:1) Would you walk us through your professional experience, highlighting where you developed key skills and experiences that prepared you for your current role at Albertsons Media Collective.2) On a previous episode of this podcast, your colleague Evan Hovorka described Albertsons Media Collective's portfolio of offerings as having “late mover's advantage.” As you thought about ensuring that Albertsons Media Collective's targeting & measurement would be best-in-class among competitive retail media platforms, what were you seeking to deliver to brands?3) Would you double click down into the targeting capabilities within Albertsons Media Collective. When creating audiences, how are brands able to leverage longitudinal purchasing behavior and how can it be applied to omnichannel media activations? How is that different from your competitive set?4) Evan argued that ROAS alone was not meaningful for brands seeking to understand real incrementality. How is Albertsons Media Collective delivering meaningful ROI measurement for the investments that brands make in your assets? How quickly are they able to get these insights?5) In your partnerships with third party partners like The Trade Desk for programmatic offsite or Pacvue for platform ad management, how do you collaborate to ensure the measurement & analytics are consistent & meaningful for brands?6) Do you have any examples of creative ways that Albertsons Media Collective is partnering with brands in performance marketing analysis to transform their media planning & investments?7) What advice do you give to brands seeking to leverage the full performance measurement services of your team and how do you measure your team's ability to deliver the service levels you have established?8) How does your team support brands seeking to leverage your measurement offerings and where are you looking to enhance your offerings in the near future?CPG Guys Website: http://CPGguys.comFMCG Guys Website: http://FMCGguys.comCPG Scoop. Website: http://CPGscoop.comRetailWit Website: http://retailwit.comDISCLAIMER: The content in this podcast episode is provided for general informational purposes only. By listening to our episode, you understand that no information contained in this episode should be construed as advice from CPGGUYS, LLC or the individual author, hosts, or guests, nor is it intended to be a substitute for research on any subject matter. Reference to any specific product or entity does not constitute an endorsement or recommendation by CPGGUYS, LLC. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.  CPGGUYS LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual's use of, reference to, or inability to use this podcast or the information we presented in this podcast.

Video Version https://vimeo.com/744164877 About the Podcast My guest today is Stephan Meyer PhD, CEO of Almademey Ltd. I have known Stephan for some years now, he being one of the first professionals when I arrived in Germany over a decade ago. I have always found our conversations quite interesting. Like me, he knows you can't hit home-runs without the risk of breaking a few windows. The conversation starts where it always starts, at the beginning. Stephan shares that his father was an electrical engineer and he hoped that Stephan would also become an electrical engineer. But Stephan found himself rather bored with the complicated and gravitated towards the complex (listen or watch the intro for a really elegant explanation for the difference of the two). As such, Stephan gravitated towards psychology. Stephan shares many highlights of his professional journey, including the journey of researching the subject for his PhD, "Sacred Cows" and how they should be sought in an organization and eliminated. And he also makes the case for the necessity for businesses to face perils and even doom every now and then which would offer the opportunity for a radical change and cleansing purge; to be reborn again better. All in, a really great session and I believe you will enjoy it. I did… About Stephan Meyer, PhD Stephan Meyer Stephan has orchestrated successful change initiatives in digital transformation for 25 years. During this time, he has held roles as CEO, Member of the Board, Program Manager, Mentor and Coach. At a rather mature age (you are never too old to learn), Stephan received his PhD in Business Administration and Management at the University of Gloucestershire in England for his research in radical change by finding and killing "sacred cows" in organizations. For his research, he interviewed interim managers, consultants, and line managers. Stephan is a forward-thinking advisor for avant-garde clients. Stephan is not for those who shrink from leading. There are bold choices and there are easy choices. And he stands for those in the front of the line – the bold and visionary, the entrepreneurs, and the risk-takers. Stephan clients are those who surprise the world by taking a leap into the future. LinkedIn Profile: https://www.linkedin.com/in/stephanmeyer/ Company: Almademey Ltd Title: CEO Website: https://stephanmeyer.com/ Headquarters:  Paphos District, Cyprus Year Founded: 2022 Company Type: Privately Held, LLC Company Size: Himself Industry Experience: Service, Healthcare, Mobility, Automotive, Life Sciences, Finance, Infrastructure, Media and others Practice Areas:  Business Psychology, Business Wargaming, Change Management, Corporate Foresight, Crisis Management, Cultural Change, Digital Transformation, Innovation Management, Lean Management, Merger & Acquisition, Multi-Project Management, Operational Excellence, Organization Design, Performance Measurement, Private Equity, Program Management, Restructuring, Service Management, Strategic Management, Turnaround

70% of the top 100 largest listed companies in six Southeast Asian nations – Indonesia, Malaysia, the Philippines, Singapore, Thailand and Vietnam – published climate-related disclosures in 2020/2021.  BUT - they fall short when it comes to measuring performance and linking them to senior executive salaries.  That's according to research conducted jointly by the National University of Singapore's (NUS) Centre for Governance and Sustainability, and non-profit independent standards organisation Global Reporting Initiative. The Afternoon Update's Rachel Kelly speaks to Prof Lawrence Loh, Director, Centre for Governance and Sustainability at NUS Business School to find out more. See omnystudio.com/listener for privacy information.

On this episode, we discuss an all-too-often underdiagnosed disease: NASH, a.k.a. nonalcoholic steatohepatitis, a severe form of “fatty liver” disease. Though NASH can affect people who are obese or diabetic with high cholesterol, it can also hit someone who's relatively healthy and who doesn't even drink alcohol. It's because of this and other factors that liver disease can be easily underdiagnosed, leading to dire consequences.A few months ago, there was a great roundtable discussion about approaches to care and treatment – and hopeful early diagnosis – for people with NASH. In April 2022, NCQA together with a team from Novo Nordisk published a white paper summarizing this roundtable. The paper was titled "A Rallying Cry: Improving Coordinated Care for People With Nonalcoholic Steatohepatitis."In our interview, we hear from Donna Cryer, President & CEO of the Global Liver Institute, and Dr. Mary Barton, NCQA Vice President for Performance Measurement, exploring new ideas for optimal primary care for liver patients.Donna Cryer, JD, is Founder and Chief Executive Officer of Global Liver Institute (GLI), the premier patient-driven liver health nonprofit operating with offices and partnerships across five continents. Moved by her own experience as a 27-year liver transplant recipient, Mrs. Cryer serves as a fierce advocate for the transformative potential of patient engagement in health policy, research, data, and system design.Mrs. Cryer serves on numerous committees and boards, including the Boards of Directors for the Council of Medical Specialty Societies (CMSS), Sibley Memorial Hospital/Johns Hopkins Medicine, and the Color of Crohns and Chronic Illness (COCCI). She holds an undergraduate degree from Harvard and a Juris Doctorate from the Georgetown University Law Center.Dr. Mary Barton, MD, serves as NCQA's Vice President for Performance Measurement. In her role, Dr. Barton oversees the development, use and maintenance of techniques NCQA uses to evaluate health care quality. She ensures the scientific integrity of NCQA measurement and research. She also leads NCQA in winning and executing health care quality measurement contracts for federal and state governments.

Rick Augsburger has worked for more than 25 years as a leader in the international development and humanitarian sector, focusing on leadership, staff resilience, program growth and strategy and is he a founding partner of the Konterra Group.   Prior to joining the KonTerra Group, Rick served as the deputy director of the Headington Institute (2007-2008), Director of Emergency Programs (1996-2005) and Deputy Director (2005-2007) for Church World Service, an international relief and development agency. He has a BA in Business Administration and is a graduate of the Harvard Business School Executive Leadership program in Performance Measurement and Management for Nonprofit Organizations.   Rick was also regional advisor for the United States Agency for International Development-OFDA in East Africa and the associate director for Mennonite Disaster Service. He brings more than twenty years of experience in humanitarian programming. He has traveled extensively working on relief and development programs in more than 70 countries. He has also led disaster rapid response teams and participated as a trainer and consultant for numerous humanitarian agencies.   From 2000 to 2005 Rick served as the co-chair of InterAction's Humanitarian Policy and Practice Committee. Prior to that he was a member of InterAction's executive board of directors and represented the U.S.-based humanitarian community on the United Nations Inter-Agency Standing Committee (IASC) Working Group.   My conversation with Rick Augsburger took place in 2021.   For more info about CWS, please check out this website. The Konterra Group is on Facebook and Twitter. You can also find Rick on Facebook.   We made a special Playlist #CWSsongs consisting of songs chosen by many of our podcast guests.   Please let me/us know via our email innovationhub@cwsglobal.org what you think about this new series. We would love to hear from you.   Please like/follow our Walk Talk Listen podcast and follow @mauricebloem on twitter and instagram.  Or check us out on our website 100mile.org (and find out more about our app (android and iPhone) that enables you to walk and do good at the same time!

Featuring Shane Dikoli, Bank of American Professor of Business Administration at the Darden School, UVA and an expert on Executive Compensation and Performance Measurement. (Recorded 4/19/22)        

Leistung, Effektivität und Effizienz sind in jedem Unternehmen wichtige Steuerungsgrößen. Diese möglichst genau zu erfassen als Grundlage unternehmerischer Entscheidungen ist die Aufgabe des Performance Measurement. Das aktuelle Standardwerk zu diesem Thema stammt von Prof. Dr. Ronald Gleich und ist 2021 schon in der dritten Auflage im Vahlen-Verlag erschienen. Ronald Gleich ist Professor für Management Practice & Control an der Frankfurt School of Finance & Management und dort Academic Director des Centers für Performance Management & Controlling. Darüber hinaus leitet er den Think Tank des Internationalen Controller Vereins, die sogennante Ideen-Werkstatt. Im Interview sprechen wir über die Neuauflage seines Buches „Performance Measurement“ und die darin beschriebenen Konzepte, Praxis-Fallstudien und konkreten Handlungsempfehlungen.   Der Performance Manager Podcast ist der erste und einzige deutschsprachige Podcast für Business Intelligence und Performance Management. Controller und CFO erhalten hier Inspirationen, Know-how und Impulse für die berufliche und persönliche Weiterentwicklung. Weitere Informationen zu Peter Bluhm, dem Macher des Podcast, finden Sie hier: https://www.atvisio.de/unternehmen/ Unsere Bitte: Wenn Ihnen diese Folge gefallen hat, hinterlassen Sie uns bitte eine 5-Sterne-Bewertung, ein Feedback auf iTunes und abonnieren diesen Podcast. Zeitinvestition: Maximal ein bis zwei Minuten. Dadurch helfen Sie uns, den Podcast immer weiter zu verbessern und Ihnen die Inhalte zu liefern, die Sie sich wünschen. Herzlichen Dank an dieser Stelle!  Sie sind ein Fan unseres Podcast? Sie finden uns auch auf diesen Kanälen: Exklusive Xing-Gruppe zum Podcast: https://bit.ly/3eKubH6 Exklusive LinkedIn-Gruppe zum Podcast: https://bit.ly/2zp6q7j Peter Bluhm auf LinkedIn: https://bit.ly/2x0WhwN Peter Bluhm auf Xing: https://bit.ly/2Kkxhne Webseite: https://atvisio.de/podcast Facebook: https://www.facebook.com/ATVISIO/ Twitter: https://twitter.com/atvisio Instagram: https://bit.ly/2KlhyEi Apple Podcast:  https://apple.co/2RUMwaK Soundcloud: https://soundcloud.com/atvisio  

Leistung, Effektivität und Effizienz sind in jedem Unternehmen wichtige Steuerungsgrößen. Diese möglichst genau zu erfassen als Grundlage unternehmerischer Entscheidungen ist die Aufgabe des Performance Measurement. Das aktuelle Standardwerk zu diesem Thema stammt von Prof. Dr. Ronald Gleich und ist 2021 schon in der dritten Auflage im Vahlen-Verlag erschienen. Ronald Gleich ist Professor für Management Practice & Control an der Frankfurt School of Finance & Management und dort Academic Director des Centers für Performance Management & Controlling. Darüber hinaus leitet er den Think Tank des Internationalen Controller Vereins, die sogennante Ideen-Werkstatt. Im Interview sprechen wir über die Neuauflage seines Buches „Performance Measurement“ und die darin beschriebenen Konzepte, Praxis-Fallstudien und konkreten Handlungsempfehlungen.   Der Performance Manager Podcast ist der erste und einzige deutschsprachige Podcast für Business Intelligence und Performance Management. Controller und CFO erhalten hier Inspirationen, Know-how und Impulse für die berufliche und persönliche Weiterentwicklung. Weitere Informationen zu Peter Bluhm, dem Macher des Podcast, finden Sie hier: https://www.atvisio.de/unternehmen/ Unsere Bitte: Wenn Ihnen diese Folge gefallen hat, hinterlassen Sie uns bitte eine 5-Sterne-Bewertung, ein Feedback auf iTunes und abonnieren diesen Podcast. Zeitinvestition: Maximal ein bis zwei Minuten. Dadurch helfen Sie uns, den Podcast immer weiter zu verbessern und Ihnen die Inhalte zu liefern, die Sie sich wünschen. Herzlichen Dank an dieser Stelle!  Sie sind ein Fan unseres Podcast? Sie finden uns auch auf diesen Kanälen: Exklusive Xing-Gruppe zum Podcast: https://bit.ly/3eKubH6 Exklusive LinkedIn-Gruppe zum Podcast: https://bit.ly/2zp6q7j Peter Bluhm auf LinkedIn: https://bit.ly/2x0WhwN Peter Bluhm auf Xing: https://bit.ly/2Kkxhne Webseite: https://atvisio.de/podcast Facebook: https://www.facebook.com/ATVISIO/ Twitter: https://twitter.com/atvisio Instagram: https://bit.ly/2KlhyEi Apple Podcast:  https://apple.co/2RUMwaK Soundcloud: https://soundcloud.com/atvisio  

Our first Australian guest is the founder of PuMP, an approach to Performance Measurement and KPI's. PuMP is a practical and engaging performance measurement approach to develop KPIs that are meaningful and measure what matters. Of course we talked with her about PuMP, but we also talked with her about other topics like Queensland, statistics, railways, weasel words, motorcycles, OKR's, KPI's, XmR's, vegan chocolate, the 1990 wool crisis, drag racing and the other Stacey Barr from Australia. So, we've talked about a lot of different topics, and even more topics are discussed. Interesting links as mentioned during the podcast are: Follow her on LinkedIn: https://www.linkedin.com/in/staceybarr/ Go visit her website: https://www.staceybarr.com/ How to visualise performance with a Xmr chart: https://www.staceybarr.com/measure-up/build-xmr-chart-kpi/ How to automate XmR signal rules in your dashboard: https://www.staceybarr.com/measure-up/can-you-automate-xmr-signal-rules-in-your-dashboard/ How to use XmR charts in Power BI: https://visuals.novasilva.com/xmrcharts_pbi/ More about weasel words: https://www.staceybarr.com/?s=weasel Do you have questions, remarks, or tips for us? Please let us know: michel@datavoorstellingen.nl or ben@datavoorstellingen.nl. #data #dataliteracy #datadriven #dataviz #datavisualisation #datavisualiseren #datadesign #kpi #okr #PuMP #measure #performance #measurement #weasel #queensland #xmr #chart #dragracing #holden #ducati #veganchocolate #ducati

In this episode, we get a look ahead, both at the future of NCQA's Quality Measurement agenda and our Quality Talks 2022 event.Dr. Eric Schneider is NCQA's recently-appointed Executive Vice President of the Quality Measurement and Research Group. In this role, he helps drive NCQA's efforts to create a more equitable health care system and to advance the move to digital quality measurement. Before that, he served as a Health Quality expert for both The Commonwealth Fund and the RAND Corporation. He taught public health policy at Harvard Medical and was a practicing primary care internist for over 25 years.But he was also co-Chair of NCQA's Committee on Performance Measurement for nearly 10 years, so he's no stranger to what we do here.Tosan Boyo is Senior Vice President for Hospital Operations at John Muir Health in the San Francisco Bay area. He also served as a leader of the San Francisco COVID-19 Operations Center, where they had the lowest case rates and highest testing rates of any high-density city in the country. Born in Nigeria and later raised in the U.S., Boyo backpacked around the world, gaining a global take on how Health Equity leads to improved Quality for all. Come see him speak, in person in Washington, DC, or online, at Quality Talks 2022.

In 2015, Meme Styles founded MEASURE to promote the use of evidence-based projects and tools to tell real-life stories behind the numbers. As a catalyst for systems change, MEASURE has grown to a fully operational nonprofit social enterprise that provides free data support to Powerful Black and Brown-led communities. So far the organization has provided over 3000 free data support hours to Black and Brown - led organizations. They are also responsible for strategic partnerships with the University of Texas, Texas Southern University and more with a goal of disrupting traditional research in exchange for Black and Brown-led lived-experience protocols. Jameila "Meme" Styles is an AARO Fellow, past- Chairwoman of Miss Juneteenth, SXSW Innovative Nonprofit Of the Year, Austin Police Chief's Award of Excellence recipient, Austin 40 under 40 WINNER 2019, past-Chairwoman of African TV5 (AFTV5) and the Austin Black Chambers 2017 Community Leader of the Year and a current MIT fellow solving for anti-racist technology. Mrs. Styles holds a Bachelor of Science in Communications, Masters Of Public Administration with a concentration on National Security, was certified in Performance Measurement through George Washington University College of Professional Studies and has a certification in Diversity, Equity + Inclusion from Cornell. She is also the wife of a US Veteran and the mother of 4.

In this episode of AFSPA Talks, COO, Kyle Longton discusses Medicare, Tricare, and the Federal Employees Health Benefits (FEHB) Program, and how they work together with Rear Adm. Christine Hunter (Ret.), MD Former Chief Medical Officer, OPM Co-Chair, NCQA Committee on Performance Measurement. AFSPA CEO, Paula S. Jakub, RHU also joins the conversation to give us more information on how Medicare coordinates benefits with the other two programs. Below are some helpful links: AFSPA webinar on Medicare: https://www.youtube.com/watch?v=wDzJnt4Rf6k Medicare Overview: https://www.afspa.org/fsbp-and-medicare/ OPM information on overseas coverage: https://www.opm.gov/healthcare-insurance/healthcare/plan-information/important-facts-about-overseas-coverage/ Military Officers Association of American Post on Medicare and TRICARE for Life: https://www.moaa.org/content/publications-and-media/news-articles/2021-news-articles/65-and-beyond-understanding-medicare-and-tricare-for-life/ Tricare4u: www.tricare4u.com  TRICARE: www.tricare.mil  

Joining Traci for today's podcast is Councilmember Matt Mahan from the City of San José, District 10 who is also running for Mayor. Councilmember Mahan shared his experiences growing up in Watsonville, California, through today and how he relates his work in the social sector to that in the private sector. Councilmember Mahan specifically compares and contrasts start-ups and venture capital to work in government. For instance, both sectors operate in environments of uncertainty and Matt helps propose some potential solutions for alleviating such within government. As part of Matt's work serving the public, he is extremely customer-centric much the same as businesses serve customers and clients. Matt highlights for us many of the questions citizens have for instance around "where does our money go?" and he shared about the 311 app that has been successful in San Jose as the initial step in performance measurement in a community that the public responded positively towards that others may want to learn more about, too. Councilmember Mahan strongly advocates for a public sector environment that creates comprehensive measurement and analysis in the performance of their community that helps us identify what didn't work in the system, and also what does work which gives us all as leaders to drive clarity, and an opportunity to empower ourselves to create better options.

This month, Cassie Dodd, Ascent Cloud's Director of Marketing, is joined by Ascent Cloud's SVP of Sales, Craig Bickley, to discuss tracking sales metrics and performance measurement. Craig shares his experiences with managing sales teams and tracking performance measurement to candidly bring you the things he's learned, and more importantly, what actually works. Cassie and Craig go over: Why sales performance measurement is importantMetric planning and where to startHow to track sales metrics and performance measurement *In this episode, Craig and Cassie reference our report with Sales Management Association. In this report, we uncover sales organizations' performance measurement approaches for financial outcomes, activity measurements, as well as adjustments made in response to the global pandemic. Check out the report here.

What factors make a pharmacy ‘successful'? What if we could boil it down to quantitative measurements and be able to prove a pharmacy's potential for success? These are the kind of questions Lisa Hines thinks about in her role as VP of Performance Measurement for the Pharmacy Quality Alliance (PQA). Join Hines and our hosts Mark and Josh as they take a deep dive into the process behind developing pharmacy metrics that can prove a pharmacy's value to health plans and payers. Hosted By: Mark Bivins, VP of Sales | Josh Howland, VP of Clinical Strategy Guest: Lisa Hines, VP of Performance Measurement at Pharmacy Quality Alliance (PQA) Want to learn more about the Catalyst Pharmacy Podcast and its hosts? Click Here Looking for more information about independent pharmacy? Visit www.PioneerRx.com

In this episode, Arun and I discuss portfolio construction and the importance of re-balancing your portfolio on a consistent basis. Arun Muralidhar, has experience in and has written extensively on asset allocation, currency management and the importance of re-balancing portfolios. Arun is Co-Founder of Mcube Investment Technologies LLC (www.mcubeit.com) and Co-Founder and Client Portfolio Manager of AlphaEngine Global Investment Solutions (AEGIS), an SEC registered investment advisor that is a subsidiary of Mcube. Both firms assist institutional investors in asset allocation, currency management and external manager oversight through customized investment advice and the award-winning AlphaEngine® technology. Arun is the author of Innovations in Pension Fund Management – Stanford University Press, 2001 (translated into Japanese and Chinese). He is also co-author with the late Prof. Franco Modigliani on a book on reforming Social Security, titled, Rethinking Pension Reform – Cambridge University Press, 2004 and edited European Pension Reform, Luxembourg Institute of International Studies, 2007. His book titled, A SMART Approach to Portfolio Management, published in 2009 lays out how the SMART Approach can be applied to all aspects of fund management and would have helped funds in 2008. Arun has served as Managing Director at FX Concepts Inc (2001-2008), Managing Director/Head of Currency Research, at J.P. Morgan Fleming Asset Management (1999-2001) and prior to that, he was Head of Research and member of the Investment Management Committee at The World Bank (1992-1999). Arun has also written a number of articles on investment finance and risk adjusted performance measurement and is a frequent speaker at industry conferences globally. He is also an Adjunct Professor of Finance at the George Washington University School of Business. He has taught courses/delivered seminars at the MIT Sloan School of Management (for Prof. Modigliani), University of Tokyo (Center for Advanced Research in Finance), George Washington University (Masters of Science in Finance), Hitotsubashi University's Graduate School of International Corporate Strategy and Nomura School of Advanced Management. He currently serves on the Advisory Board for the Journal of Performance Measurement and Journal for Investment Consulting and has served on the Board of the Journal of Asset Management. He holds a PhD in Managerial Economics from the MIT Sloan School of Management and a B.S. from Wabash College. https://www.linkedin.com/in/arun-muralidhar-74b2182/ https://www.mcubeit.com/ https://twitter.com/macrocrunch https://macrocrunch.substack.com/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/sean-bill/message

Listen NowMeasuring health care quality and outcomes effectively and efficiently remains a daunting task.  Quality measures are largely seen as too process versus outcome focused, substantially irrelevant to patients and insufficiently aligned between and among payers.  Measuring care or care quality, ironically, can and does detract from actual care delivery, can have no relationship to spending efficiency and on its own is costly.  A recent article published in Health Affairs found physician practices spent over $15 billion in 2014 in reporting quality measures.  Concerning the Medicare program's quality measurement activities, MedPAC in a 2014 report to the Congress went so far as to state, "Medicare's current quality measurement approach as gone off the rails." During this 23 minute conversation Dr. Burstin briefly describes the work of the National Quality Forum (NQF), the work done by the CMS-led Core Measure Collaborative, quality measurement under the CMS proposed MACRA (Medicare Access and CHIP Reauthorization Act) rule, risk adjusting measures for socio-demographic factors, the role of PREMS and PROMS or patient reported experience and outcome measures and correlating care quality and spending or measuring for healthcare value.  Dr. Helen Burstin is the Chief Scientific Officer at the NQF.  Prior to serving in her current position, Dr. Burstin was NQF's Senior Vice President for Performance Measurement.  Prior to NQF Dr. Burstin was the Director of the Center for Primary Care at the DHHS Agency for Healthcare Research and Quality (AHRQ).  Prior to AHRQ, Dr. Burstin was an Assistant Professor at Harvard Medical School and the Director of Quality Measurement at the Brigham and Woman's Hospital in Boston.  Dr. Burstin has published more than 80 articles and book chapters on quality, safety and disparities.  She was recently selected as a 2015-2016 Baldridge Executive Fellow.  She currently is also is a Professorial Lecturer in the Department of Health and Policy and a Clinical Associate Professor of Medicine at George Washington University and serves as a preceptor in internal medicine.For information concerning NQF go to: http://www.qualityforum.org/Home.aspx This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thehealthcarepolicypodcast.com